CEL-SCI
Corporation (CEL-SCI) is a clinical-stage biotechnology company
focused on finding the best way to activate the immune system to
fight cancer and infectious diseases. Its lead investigational
therapy Multikine® (Leukocyte Interleukin, Injection) is
currently in a pivotal Phase 3 clinical trial for patients who are
newly diagnosed with advanced primary squamous cell carcinoma of
the head and neck, for which CEL-SCI has received Orphan Drug
Status from the U.S. Food and Drug Administration, or FDA. The
study was fully enrolled with 928 patients in September 2016. The
study’s primary end-point is a 10% increase in overall
survival of patients between the two main comparator groups in
favor of the group receiving the Multikine treatment regimen. The
determination if the study’s primary end-point is met will
occur when there are a total of 298 deaths in those two groups. If
the primary end-point of this global study is achieved, CEL-SCI
expects to use the results to support a Biologics License
Application, or BLA, to the FDA for Multikine for neoadjuvant
therapy in patients with squamous cell carcinoma of the head and
neck, or SCCHN (hereafter also referred to as advanced primary head
and neck cancer).
CEL-SCI’s
investigational immunotherapy, Multikine, is being used in a
different way than cancer immunotherapy is usually used. It is
given before any other therapy has been administered because that
is when the immune system is thought to be strongest (i.e., as a
neoadjuvant). It is also
administered locally around the tumors and near the draining lymph
node. For example,
in the Phase 3 clinical trial,
Multikine was given locally for three weeks, five days per week as
a first line treatment before surgery, radiation and/or
chemotherapy. The goal is to help the intact immune system kill the
micro metastases that usually cause recurrence of the cancer. In
short, CEL-SCI believes that local administration of this
neoadjuvant therapy and administration before weakening of the
immune system by surgery, chemotherapy and radiation will result in
improved outcomes and better overall survival rates for patients
suffering from head and neck cancer.
CEL-SCI
is also investigating a peptide-based immunotherapy as a vaccine
for rheumatoid arthritis using its LEAPS technology platform.
CEL-SCI was awarded a Phase 2 Small Business Innovation Research
(SBIR) grant in the amount of $1.5 million from the National
Institutes of Health (NIH) in September 2017. This grant will
provide funding to allow CEL-SCI to advance its first LEAPS product
candidate, CEL-4000, towards an Investigational New Drug (IND)
application.
CEL-SCI
was formed as a Colorado corporation in 1983. CEL-SCI’s
principal office is located at 8229 Boone Boulevard, Suite 802,
Vienna, VA 22182. CEL-SCI’s telephone number is 703-506-9460
and its website is www.cel-sci.com. CEL-SCI does not incorporate
the information on its website into this report, and you should not
consider it part of this report.
CEL-SCI
makes its electronic filings with the Securities and Exchange
Commission (SEC), including its annual reports on Form 10-K,
quarterly reports on Form 10-Q, current reports on Form 8-K and
amendments to these reports available on its website free of charge
as soon as practicable after they are filed or furnished to the
SEC.
CEL-SCI’S PRODUCTS
CEL-SCI
is a clinical-stage biotechnology company dedicated to research and
development directed at improving the treatment of cancer and other
diseases by using the immune system, the body’s natural
defense system. CEL-SCI is currently focused on the development of
the following product candidates and technologies:
1)
Multikine,
an investigational immunotherapy under development for
the potential treatment of certain head and neck
cancers;
2)
L.E.A.P.S. (Ligand
Epitope Antigen Presentation System) technology, or LEAPS, with two
investigational therapies, CEL-2000 and CEL-4000, vaccine product
candidates under development for the potential treatment of
rheumatoid arthritis, and LEAPS-H1N1-DC, a product candidate under
development for the potential treatment of pandemic influenza in
hospitalized patients,
MULTIKINE
CEL-SCI’s
lead investigational therapy, Multikine, is currently being
developed as a potential therapeutic agent directed at using the
immune system to produce an anti-tumor immune response. Data from
Phase 1 and Phase 2 clinical trials suggest that Multikine may help
the immune system “see” the tumor and then attack it,
enabling the body’s own anti-tumor immune response to fight
the tumor. Multikine is the trademark that CEL-SCI has registered
for this investigational therapy, and this proprietary name is
subject to review by the FDA, in connection with CEL-SCI’s
future anticipated regulatory submission for approval in the United
States. Multikine has not been licensed or approved for sale,
barter or exchange by the FDA or any other regulatory agency, such
as the European Medicine Agency, or EMA, and neither its safety nor
its efficacy been established.
Multikine is an
immunotherapy product candidate comprised of a patented defined
mixture of 14 human natural cytokines. Upon commercial approval,
CEL-SCI intends to manufacture it in a proprietary manner in
CEL-SCI’s manufacturing facility. CEL-SCI spent over 10 years
and more than $80 million developing and validating the
manufacturing process for Multikine. The pro-inflammatory cytokine
mixture includes interleukins, interferons, chemokines and
colony-stimulating factors, which contain elements of the
body’s natural mix of defenses against cancer.
Multikine is
designed to be used in a different way than cancer immunotherapy is
generally being used. Generally, cancer immunotherapy is given to
patients who have already failed other treatments such as surgery,
radiation and/or chemotherapy and most of the time it is
administered systemically. Multikine on the other hand is
administered locally to treat tumors and their microenvironment
before any other therapy has been administered because it is
believed that this is the time when the immune system would be most
amenable to activation against the tumor. For example, during
the dosing phase of the ongoing Phase 3 clinical trial, Multikine
was injected locally around the tumor and near the adjacent
draining lymph nodes as a first line of treatment before surgery,
radiation and/or chemotherapy. The goal is to help the intact
immune system recognize and kill the tumor micro metastases that
usually cause recurrence of the cancer. In short, CEL-SCI believes
that the local administration and administration of Multikine and
its administration before weakening of the immune system by
surgery, chemotherapy and radiation will result in better
anti-tumor response than if Multikine were administered as a
second- or later-line therapy. In clinical studies of Multikine,
administration of the investigational therapy to head and neck
cancer patients has demonstrated the potential for lesser or no
appreciable toxicity.
Source: Adapted from Timar et al., Journal of Clinical Oncology
23(15) May 20, 2005
The
first indication CEL-SCI is pursuing for its investigational drug
product candidate Multikine is an indication for the neoadjuvant
therapy in patients with squamous cell carcinoma of the head and
neck, or SCCHN (hereafter also referred to as advanced primary head
and neck cancer).
SCCHN
represents one type of head and neck cancer, and CEL-SCI believes
that there is a large, unmet medical need among head and neck
cancer patients as a whole. CEL-SCI believes the last FDA approval
of a therapy indicated for the treatment of advanced primary head
and neck cancer was over 50 years ago. In the aggregate, head and
neck cancer represents about 6% of the world’s cancer cases,
with approximately 650,000 patients diagnosed worldwide each year,
of which approximately 60,000 patients diagnosed annually in the
United States and approximately 105,000 patients diagnosed annually
in Europe. Multikine investigational immunotherapy has been granted
Orphan Drug designation for neoadjuvant therapy in patients with
SCCHN by the FDA in the United States.
The
current Phase 3 study for Multikine was designed with the objective
that, if the study endpoint, which is an improvement in overall
survival of the subjects treated with the Multikine treatment
regimen plus the current Standard of Care (SOC) as compared to
subjects treated with the current SOC only, is satisfied, the study
results are expected to be used to support applications that
CEL-SCI plans to submit to regulatory agencies in order to seek
commercial marketing approvals for Multikine in major markets
around the world. The assessment of whether the primary study
endpoint was met can only be made when a certain number of events
(deaths) have occurred in these two main comparator groups of the
study.
The
primary endpoint for the protocol for this Phase 3 head and neck
cancer study required that a 10% increase in overall survival be
obtained in the Multikine group which also is administered CIZ (CIZ
= low dose (non-chemotherapeutic) of cyclophosphamide, indomethacin
and Zinc-multivitamins) all of which are thought to enhance
Multikine activity), plus SOC (Surgery + Radiotherapy or
Chemoradiotherapy) arm of the study over the control comparator
(SOC alone) arm. As the study was designed, the final determination
of whether this endpoint had been successfully reached can only be
determined when 298 events have occurred in the combined comparator
arms of the study.
Nine
hundred twenty-eight (928) newly diagnosed head and neck cancer
patients have been enrolled in this Phase 3 cancer study across 24
countries and all the patients who have completed treatment
continue to be followed for protocol-specific outcomes in
accordance with the study protocol. The last patient was enrolled
in the study in September 2016. Approximately 135 patients were
enrolled in the study from 2011 to 2013, about 195 were enrolled in
2014, about 340 in 2015, and about 260 in 2016. The Phase 3 study
protocol assumed an overall survival rate of about 55% at 3 years
for the SOC treatment group alone. An analysis conducted using the
Surveillance, Epidemiology, and End Results, or SEER U.S.
government data base for the same study population as CEL-SCI
enrolled in this Phase 3 study and covering the years 2011-2016
(when the patients were enrolled), shows that the standard of care
for these patients has not resulted in an improvement in survival.
In fact, the U.S. survival of the specific type of patients
enrolled in the Phase 3 study during the study years was only about
47% at 3 years and about 37% at 5 years. At this point, all
patients enrolled in the study are being followed-up as required by
the study protocol.
This
trial is currently under the management of two clinical research
organizations, or CROs: ICON Inc., or ICON, and Ergomed Clinical
Research Limited, or Ergomed.
Since
CEL-SCI launched its Phase 3 clinical trial for Multikine, CEL-SCI
has incurred expenses of approximately $55.8 million as of
September 30, 2019 on direct costs for the Phase 3 clinical trial.
CEL-SCI estimates it will incur additional expenses of
approximately $4.5 million for the remainder of the Phase 3
clinical trial. It should be noted that this estimate is based only
on the information currently available in CEL-SCI’s contracts
with the CROs responsible for managing the Phase 3 clinical trial
and does not include other related costs, e.g., preparations for
the potential commercial manufacture of the drug. This number may
be affected by the rate and speed of death accumulation in the
study, foreign currency exchange rates, and many other factors,
some of which cannot be foreseen today. It is therefore possible
that the cost of the Phase 3 clinical trial may be higher than
currently estimated.
Ultimately, the
decision as to whether CEL-SCI’s drug product candidate is
safe and effective can only be made by the FDA and/or by other
regulatory authorities based upon an assessment of all of the data
from an entire drug development program submitted as part of an
application for marketing approval. As detailed in the Risk Factors
in this report, the current Phase 3 clinical study for
CEL-SCI’s investigational drug may or may not be able to be
used as the pivotal study supporting a marketing application in the
United States, and, if not, at least one entirely new Phase 3
pivotal study would need to be conducted to support a marketing
application in the United States.
Development Agreements for Multikine
In
August 2008, CEL-SCI signed an agreement with Teva Pharmaceutical
Industries Ltd., or Teva, that gives Teva the exclusive right and
license to market, distribute and sell Multikine, if approved, in
Israel and Turkey for treatment of head and neck cancer. The
agreement terminates on a country-by-country basis 10 years after
the product launch in each country or upon a material breach or
upon bankruptcy of either party. The agreement will automatically
extend for additional two year terms unless either party gives
notice of its intent not to extend the agreement. If CEL-SCI
develops Multikine for other oncology indications and Teva
indicates a desire to participate, the parties have agreed to
negotiate in good faith with respect to Teva’s participation
and contribution in future clinical trials.
Teva
has agreed to use all reasonable efforts to obtain regulatory
approval to market and sell Multikine in its territory at its own
cost and expense. Pursuant to the agreement, it is CEL-SCI’s
responsibility to supply Multikine and Teva’s responsibility
to sell Multikine, if approved by regulatory authorities in the
relevant countries. Net sales will be divided 50/50 between the two
parties. Teva also initially agreed to fund certain activities
relating to the conduct of a clinical trial in Israel as part of
the global Phase 3 trial for Multikine. In January 2012, pursuant
to an assignment and assumption agreement between CEL-SCI, Teva and
GCP Clinical Studies Ltd., or GCP, Teva transferred all of its
rights and obligations concerning the Phase 3 trial in Israel to
GCP. GCP is now operating the Phase 3 trial in Israel pursuant to a
service agreement with CEL-SCI.
In July
2011, Serbia and Croatia were added to Teva’s territory,
pursuant to a joinder agreement between CEL-SCI and PLIVA Hrvatska
d.o.o., or PLIVA, an affiliate of Teva’s, subject to similar
terms as described above.
In
consideration for the rights granted by CEL-SCI to PLIVA under the
joinder agreement, CEL-SCI will be paid by PLIVA (in U.S.
dollars):
●
$100,000 upon EMA
grant of Marketing Authorization for Multikine;
●
$50,000 upon
Croatia’s grant of reimbursement status for Multikine in
Croatia; and
●
$50,000 upon
Serbia’s grant of reimbursement status for Multikine in
Serbia.
In
November 2000, CEL-SCI signed an agreement with Orient Europharma
Co., Ltd., or Orient Europharma, of Taiwan, which was amended in
October 2008 and again in June 2010. Pursuant to this agreement, as
amended, Orient Europharma has the exclusive marketing and
distribution rights to Multikine, if approved by regulatory
authorities, for head and neck cancer, naso-pharyngeal cancer and
potentially cervical cancer indications in Taiwan, Singapore,
Malaysia, Hong Kong, the Philippines, South Korea, Australia and
New Zealand. CEL-SCI has granted Orient Europharma the first right
of negotiation with respect to Thailand and China.
The
agreement requires Orient Europharma to fund 10% of the cost of the
clinical trials needed to obtain marketing approvals in these
countries for head and neck cancer, naso-pharyngeal cancer and
potentially cervical cancer. Orient Europharma has set up clinical
centers for the Phase 3 trial in Taiwan, Malaysia, the Philippines
and Thailand and has made further financial contributions towards
the cost of the Phase 3 clinical trial.
If Multikine is approved for sale, Orient Europharma will purchase
Multikine from CEL-SCI for 35% of the gross selling price in each
country. Orient
Europharma is obligated to use the same diligent efforts to
develop, register, market, sell and distribute Multikine in its
territory as with its own products or other licensed
products.
The
agreement will terminate on a country-by-country basis 15 years
after the product approval for Multikine in each country, at which
point the agreement will be automatically extended for successive
two year periods, unless either party gives notice of its intent
not to extend the agreement. The agreement may also be terminated
upon bankruptcy of either party or material misrepresentations that
are not cured within 60 days. If the agreement ends before the 15
year term through no fault of either party, CEL-SCI will reimburse
Orient Europharma for a prorated part of Orient Europhorma’s
costs towards the clinical trials of Multikine. If Orient
Europharma fails to make certain minimum purchases of Multikine
during the term of the agreement, Orient Europhorma’s rights
to the territory will become non-exclusive.
CEL-SCI
has a licensing agreement with Byron Biopharma LLC, or Byron, under
which CEL-SCI granted Byron an exclusive license to market and
distribute Multikine in the Republic of South Africa, if approved.
This license will terminate 20 years after marketing approval in
South Africa or after bankruptcy or uncured material breach. After
the 20-year period has expired, the agreement will be automatically
extended for successive two year periods, unless either party gives
notice of its intent not to extend the agreement.
Pursuant to the
agreement, Byron will be responsible for registering Multikine in
South Africa. If Multikine is approved for sale in South Africa,
CEL-SCI will be responsible for manufacturing the product, while
Byron will be responsible for sales in South Africa. Sales revenues
will be divided between CEL-SCI and Byron. CEL-SCI will be paid
fifty (50%) percent of the net sales of Multikine.
LEAPS
CEL-SCI’s
patented T-cell Modulation Process, referred to as LEAPS (Ligand
Epitope Antigen Presentation System), uses
“heteroconjugates” to direct the body to choose a
specific immune response. LEAPS is designed to stimulate the human
immune system to more effectively fight bacterial, viral and
parasitic infections as well as autoimmune conditions, allergies,
transplantation rejection and cancer, when it cannot do so on its
own. Intended to be administered like a vaccine, LEAPS combines
T-cell binding ligands with small, disease associated, peptide
antigens and may provide a new method to treat and prevent certain
diseases.
The
ability to generate a specific immune response is important because
many diseases are often not combated effectively due to the
body’s selection of the “inappropriate” immune
response. The capability to specifically reprogram an immune
response may offer a more effective approach than existing vaccines
and drugs in attacking an underlying disease.
On
September 19, 2017, CEL-SCI announced that it had been awarded a
Phase 2 Small Business Innovation Research (SBIR) grant in the
amount of $1.5 million from the National Institute of Arthritis and
Musculoskeletal and Skin Diseases, or NIAMS, which is part of the
U.S. National Institutes of Health (NIH). This grant will provide
funding to allow CEL-SCI to advance its first LEAPS product
candidate, CEL-4000, towards an Investigational New Drug (IND)
application for a Phase 1 safety study, by funding IND enabling
studies and additional mechanism of action studies, among other
preclinical development activities. Work on CEL-4000 is being
conducted at CEL-SCI’s research laboratory and Rush
University Medical Center in Chicago, Illinois in the laboratories
of Tibor Glant, MD, Ph.D., Jorge O. Galante Professor of Orthopedic
Surgery and Katalin Mikecz, MD, Ph.D. Professor of Orthopedic
Surgery & Biochemistry. The SBIR grant was awarded based on
published data described below by Dr. Glant's team in collaboration
with CEL-SCI showing that the administration of a proprietary
peptide using CEL-SCI's LEAPS technology prevented the development,
and lessened the severity, including inflammation, of experimental
proteoglycan induced arthritis (PGIA or GIA) when it was
administered after the disease was induced in animals.
In May
2019, CEL-SCI announced that a newly discovered LEAPS conjugate
vaccine acts alone and can complement CEL-4000 therapeutically when
administered in combination to an animal model of Rheumatoid
Arthritis (RA). This new LEAPS conjugate appears to act on T cell
pathways by a new mechanism that is different from the pathways
used by the CEL-4000 vaccine. The data was presented at the
American Association of Immunologists 103th Annual Meeting
(Immunology 2019) by Daniel Zimmerman, Ph.D., CEL-SCI’s
Senior Vice President of Research, Cellular Immunology. The work
was performed in conjunction with researchers at Rush University
Medical Center, Chicago, Illinois and was funded by the SBIR Phase
2 Grant.
In July
2019, one of CEL-SCI’s collaborators from Rush, Dr. Adrienn
Markovics presented new LEAPS data at i-Chem2019, International
Conference on Immunity and Immunochemistry. Data presented was for
a new second RA vaccine discovered which acts alone and can
complement the existing CEL-4000 RA vaccine in an animal model of
RA. The combination of the two RA vaccines provided not only
broader epitope coverage, but also a greater therapeutic effect
than either vaccine alone. The LEAPS work was performed in
conjunction with researchers at CEL-SCI on CEL-4000 and a newly
discovered LEAPS conjugate, DerG-PG275Cit. Both vaccines were
evaluated alone and in combination in the model of proteoglycan
[PG] induced arthritis (PGIA) called recombinant PG G1
domain-induced arthritis (GIA), an autoimmune mouse model of
RA.
Prior
to the SBIR Phase 2 grant, CEL-SCI was awarded a Phase 1 SBIR grant
in the amount of $225,000 from NIAMS. This grant funded the
development of CEL-SCI’s LEAPS technology as a potential
treatment for rheumatoid arthritis, an autoimmune disease of the
joints. The work was conducted at Rush University Medical Center in
Chicago, Illinois in the laboratories of Tibor Glant, MD, Ph.D.,
Katalin Mikecz, MD, Ph.D., and Allison Finnegan, Ph.D. Professor of
Medicine.
With
the support of these SBIR grants, CEL-SCI is developing two new
drug candidates, CEL-2000 and CEL-4000, as potential rheumatoid
arthritis therapeutic vaccines. The data from animal studies using
the CEL-2000 treatment vaccine suggests that it could be used
against rheumatoid arthritis with fewer administrations than those
required by other anti-rheumatoid arthritis treatments currently on
the market for arthritic conditions associated with the Th17
signature cytokine TNF-a. The preclinical data for CEL-4000
indicates it could be used against rheumatoid arthritis where a Th1
signature cytokine (IFN-c) is dominant. CEL-2000 and CEL-4000 each
have the potential to become a personalized, disease-specific
therapy, that acts at an earlier step in the disease process than
current therapies, and which may be useful in patients not
responding to existing rheumatoid arthritis therapies. CEL-SCI
believes this represents a large unmet medical need in the
rheumatoid arthritis market.
In
February 2017 and November 2016, CEL-SCI announced preclinical data
that demonstrate its investigational new drug candidate CEL-4000
has the potential for use as a therapeutic vaccine to treat
rheumatoid arthritis. This study was supported in part by the SBIR
Phase I Grant and was conducted in collaboration with Drs. Katalin
Mikecz and Tibor Glant, and their research team at Rush University
Medical Center in Chicago, IL.
In
March 2015, CEL-SCI and its collaborators published a review
article on vaccine therapies for rheumatoid arthritis based in part
on work supported by the SBIR Phase 1 grant. The article is
entitled “Rheumatoid arthritis vaccine therapies:
perspectives and lessons from therapeutic Ligand Epitope Antigen
Presentation System vaccines for models of rheumatoid
arthritis” and was published in Expert Review of Vaccines 1 -
18 and can be found online at http://www.ncbi.nlm.nih.gov/pubmed/25787143.
Using
the LEAPS technology, CEL-SCI has also tested in preclinical
studies a potential peptide treatment for H1N1 (swine flu)
hospitalized patients. This LEAPS flu treatment is designed
to focus on the conserved, non-changing epitopes of the different
strains of Type A Influenza viruses (H1N1, H5N1, H3N1, etc.),
including “swine”, “avian or bird”, and
“Spanish Influenza”, in order to minimize the chance of
viral “escape by mutations” from immune recognition.
Therefore one should think of this treatment not really as an H1N1
treatment, but as a potential pandemic flu treatment.
CEL-SCI’s LEAPS flu treatment contains epitopes known to be
associated with immune protection against influenza in animal
models.
In May
2011 NIAID scientists presented data at the Keystone Conference on
“Pathogenesis of Influenza: Virus-Host Interactions” in
Hong Kong, China, showing the positive results of efficacy studies
in mice of LEAPS H1N1 activated dendritic cells (DCs) to treat the
H1N1 virus. Scientists at the NIAID found that H1N1-infected mice
treated with LEAPS-H1N1 DCs showed a survival advantage over mice
treated with control DCs. The work was performed in collaboration
with scientists led by Kanta Subbarao, M.D., Chief of the Emerging
Respiratory Diseases Section in NIAID’s Division of
Intramural Research, part of the National Institutes of Health,
USA.
In July
2013, CEL-SCI announced the publication of the results of influenza
studies by researchers from the NIAID in the Journal of Clinical
Investigation (www.jci.org/articles/view/67550).
The studies described in the publication show that when
CEL-SCI’s investigational J-LEAPS Influenza Virus treatments
were used “in vitro” to activate DCs, these activated
DCs, when injected into influenza infected mice, arrested the
progression of lethal influenza virus infection in these mice. The
work was performed in the laboratory of Dr. Subbarao.
Accordingly, even
though the various LEAPS vaccine candidates have not yet been given
to humans, they have been tested in vitro with human cells. They
have induced similar cytokine responses that were seen in these
animal models, which may indicate that the LEAPS technology might
translate to humans. The LEAPS candidates have demonstrated
protection against lethal herpes simplex virus (HSV1) and H1N1
influenza infection, as a prophylactic or therapeutic agent in
animals. They have also shown some level of activity in animals in
two autoimmune conditions, curtailing and sometimes preventing
disease progression in arthritis and myocarditis animal models.
CEL-SCI’s belief is that the LEAPS technology, once developed
and approved as safe and effective for humans, may be a significant
alternative to the vaccines currently available on the market for
these diseases.
None of
the LEAPS investigational products have been approved for sale,
barter or exchange by the FDA or any other regulatory agency for
any use to treat disease in animals or humans. The safety or
efficacy of these products has not been established for any use.
Lastly, no definitive conclusions can be drawn from the
early-phase, preclinical-trials data involving these
investigational products. Before obtaining marketing approval from
the FDA in the United States, and by comparable agencies in most
foreign countries, these product candidates must undergo rigorous
preclinical and clinical testing which is costly and time consuming
and subject to unanticipated delays. There can be no assurance that
these approvals will be granted.
INTELLECTUAL PROPERTY
Patents
and other proprietary rights are essential to CEL-SCI’s
business. CEL-SCI files patent applications to protect its
technologies, inventions and improvements to its inventions that
CEL-SCI considers important to the development of its business.
CEL-SCI’S intellectual property portfolio covers its
proprietary technologies, including Multikine and LEAPS, by
multiple issued patents and pending patent applications in the
United States and in key foreign markets.
Multikine is
protected by a U.S. patent, which is a composition-of-matter patent
issued in May 2005 that, in its current format, expires in 2023.
Additional composition-of-matter patents for Multikine have been
issued in Germany (issued in June 2011 and currently set to expire
in 2025), China (issued in May 2011 and currently set to expire in
2024), Japan (issued in November 2012 and currently set to expire
in 2025), and three in Europe (issued in September 2015, May 2016
and October 2017, currently set to expire in 2025 and 2026). The
most recent patent issued in October 2017, patent # EP 1 879 618
B1, titled “A Method for Modulating HLA Class II Tumor Cell
Surface Expression With A Cytokine Mixture,” addresses
Multikine’s mechanism of action to make tumors more visible
to the immune system. This new patent is important because, along
with the other Multikine issued patents, it addresses how Multikine
enables the immune system to recognize and attack the tumor. One
way tumor cells evade the immune system is by expressing human
leukocyte antigens (HLA) on the tumor cell surface, thus appearing
as ‘self’ to the immune cells and therefore the tumor
cells are not attacked. It is important to note that the tumors of
the Multikine-treated responders in CEL-SCI’s prior Phase 2
studies had no HLA Class II expressed on the cell surface following
Multikine treatment as compared to controls. This points to
Multikine’s ability to modulate HLA expression on the tumor
cell surface, thereby allowing the immune system to recognize and
attack the tumor.
In
addition to the patents that offer certain protections for
Multikine, the method of manufacture for Multikine, a complex
biological product, is held by CEL-SCI as a trade
secret.
LEAPS
is protected by patents in the United States issued in February
2006, April 2007, August 2007, January 2019 and March 2019. The
LEAPS patents, which expire in 2021, 2022, 2021 and three in 2032,
respectively, include overlapping claims, with composition of both
matter (new chemical entity), process and methods-of-use, to
maximize and extend the coverage in their current format. One
issued U.S. application is a joint application with Northeast Ohio
Medical University (“Neoucom”) and CEL-SCI will share
the ability to use the patent, unless CEL-SCI licenses the rights
to the patent from Neoucom. In October 2017, a patent was issued in
Europe for LEAPS, which expires in 2029.
CEL-SCI
has four patent applications pending in the United States and one
in Europe for LEAPS, which, if issued, would extend protection
through 2034, subject to any potential patent term
extensions.
As of
December 12, 2019, there were no contested proceedings and/or third
party claims with respect to CEL-SCI’s patents or patent
applications.
MANUFACTURING FACILITY
Before
starting the Phase 3 clinical trial, for reasons related to
regulatory considerations, CEL-SCI built a dedicated manufacturing
facility to produce its investigational biological product
candidate Multikine. This facility produced multiple clinical lots
for the Phase 3 clinical trial and has also passed quality systems
review by a European Union Qualified Person on several occasions.
At the present time, while clinical supplies of Multikine are no
longer needed and commercial approval remains subject to the
completion of our Phase 3 trial and submission of marketing
applications to the FDA and other regulatory authorities, this
manufacturing facility is not actively engaged in the production of
any drug or biological products. CEL-SCI is currently preparing the
manufacturing facility for the potential commercial manufacture of
Multikine.
CEL-SCI’s
lease on the manufacturing facility expires on October 31,
2028. CEL-SCI completed
validation of its manufacturing facility in January 2010. See Item
2 of this report for more information concerning the terms of this
lease.
GOVERNMENT REGULATION
The FDA
and other regulatory authorities at federal, state and local levels
and in foreign countries extensively regulate, among other things,
the research, development, testing, manufacture, quality control,
import, export, safety, effectiveness, labeling, packaging,
storage, distribution, record keeping, approval, advertising,
promotion, marketing and post-approval monitoring and reporting of
biologics such as those CEL-SCI is developing. CEL-SCI, along with
third party contractors, will be required to navigate the various
preclinical, clinical and commercial approval requirements of the
governing regulatory agencies of the countries in which it wishes
to conduct studies or seek approval or licensure of its product
candidates. The process of obtaining regulatory approvals and the
subsequent compliance with appropriate federal, state, local, and
foreign statutes and regulations requires the expenditure of
substantial time and financial resources.
U.S. Food and Drug Administration Regulation of Biological
Products
In the
United States, the FDA regulates biological products under the
Federal Food, Drug, and Cosmetic Act, or FDCA, and the Public
Health Service Act, or PHSA, and their implementing regulations.
The process required by the FDA before biological product
candidates may be marketed in the United States generally involves
the following:
●
completion of
preclinical laboratory tests and animal studies performed in
accordance with the FDA’s Good Laboratory Practice, or GLP,
regulations;
●
submission to the
FDA of an investigational new drug application, or IND, which must
become effective before clinical trials may begin and must be
updated annually;
●
approval by an
independent Institutional Review Board, or IRB, or ethics committee
at each clinical site before the trial is initiated;
●
performance of
adequate and well-controlled human clinical trials in compliance
with Good Clinical Practice, or GCP, regulations to establish the
safety, purity and potency of the proposed biologic product
candidate for its intended purpose;
●
preparation of and
submission to the FDA of a Biologics License Application, or BLA,
after completion of clinical trials;
●
satisfactory
completion of an FDA Advisory Committee review, if
applicable;
●
a determination by
the FDA within 60 days of its receipt of a BLA to file the
application for review;
●
satisfactory
completion of an FDA pre-approval inspection of the manufacturing
facility or facilities at which the proposed product is produced to
assess compliance with current Good Manufacturing Practice, or
cGMP, requirements and to assure that the facilities, methods and
controls are adequate to preserve the biological product’s
continued safety, purity and potency, and of selected clinical
investigations to assess compliance with GCPs; and
●
FDA review and
approval of the BLA to permit commercial marketing of the product
for particular indications for use in the United
States.
Prior
to commencing the first clinical trial with a product candidate in
the U.S., CEL-SCI must submit an IND to the FDA. An IND is a
request for authorization from the FDA to administer an
investigational product to humans. The central focus of an IND
submission is on the general investigational plan and the
protocol(s) for human studies. The IND also includes results of
animal and in vitro studies assessing the toxicology,
pharmacokinetics, pharmacology, and pharmacodynamic characteristics
of the product; chemistry, manufacturing, and controls information;
and any available human data or literature to support the use of
the investigational product. An IND must become effective before
human clinical trials may begin. The IND automatically becomes
effective 30 days after receipt by the FDA, unless the FDA, within
the 30-day time period, raises safety concerns or questions about
the proposed clinical trial. In such a case, the IND may be placed
on clinical hold and the IND sponsor and the FDA must resolve any
outstanding concerns or questions before the clinical trial can
begin. Submission of an IND therefore may or may not result in FDA
authorization to commence a clinical trial.
Clinical trials
involve the administration of the investigational product to human
subjects under the supervision of qualified investigators in
accordance with GCPs, which include the requirement that all
research subjects provide their informed consent for their
participation in any clinical study. Clinical trials are conducted
under protocols detailing, among other things, the objectives of
the study, the parameters to be used in monitoring safety and the
effectiveness criteria to be evaluated. A separate submission to
the existing IND must be made for each successive clinical trial
conducted during product development and for any subsequent
protocol amendments. Furthermore, an independent IRB for each site
proposing to conduct the clinical trial must review and approve the
plan for any clinical trial and its informed consent form before
the clinical trial commences at that site, and must monitor the
study until completed. Regulatory authorities, the IRB or the
sponsor may suspend a clinical trial at any time on various
grounds, including a finding that the subjects are being exposed to
an unacceptable health risk. Some studies also include oversight by
an independent group of qualified experts organized by the clinical
study sponsor, known as a data safety monitoring board (DSMB) or
independent data monitoring committee (IDMC), which provides
recommendations for whether or not a study should move forward at
designated check points based on access to certain data from the
study and may suggest halting the clinical trial if it determines
that there is an unacceptable safety risk for subjects or other
grounds, such as no demonstration of efficacy. There are also
requirements governing the reporting of ongoing clinical studies
and clinical study results to public registries.
For
purposes of approval of a Biologics License Application, or BLA,
human clinical trials are typically conducted in three or four
sequential phases that may overlap.
● Phase
1 — The investigational product is initially introduced into
healthy human subjects or patients with the target disease or
condition. These studies are designed to test the safety, dosage
tolerance, absorption, metabolism and distribution of the
investigational product in humans, the side effects associated with
increasing doses.
● Phase 2 — The investigational
product is administered to a limited patient population with a
specified disease or condition to evaluate the preliminary
efficacy, optimal dosages and dosing schedule and to identify
possible adverse side effects and safety risks. Multiple Phase 2
clinical trials may be conducted to obtain information prior to
beginning larger and more expensive Phase 3 clinical
trials.
● Phase
3 — The investigational product is administered to an
expanded patient population to further evaluate dosage, to provide
statistically significant evidence of clinical efficacy and to
further test for safety, generally at multiple geographically
dispersed clinical trial sites. These clinical trials are intended
to establish the overall risk/benefit ratio of the investigational
product and to provide an adequate basis for product
approval.
● Phase 4 — In
some cases, the FDA may require, or companies may voluntarily
pursue, additional clinical trials after a product is approved to
gain more information about the product. FDA may also make these
so-called Phase 4 or post-marketing studies a condition to approval
of the BLA.
Phase
1, Phase 2 and Phase 3 testing may not be completed successfully
within a specified period, if at all, and there can be no assurance
that the data collected will support FDA approval or licensure of
the product. Concurrent with clinical trials, companies may
complete additional animal studies and develop additional
information about the biological characteristics of the product
candidate, and must finalize a process for manufacturing the
product in commercial quantities in accordance with cGMP
requirements. The manufacturing process must be capable of
consistently producing quality batches of the product candidate
and, among other things, must develop methods for testing the
identity, strength, quality and purity of the final product.
Additionally, appropriate packaging must be selected and tested and
stability studies must be conducted to demonstrate that the product
candidate does not undergo unacceptable deterioration over its
shelf life.
BLA
Submission and Review by the FDA
Assuming successful
completion of all required testing in accordance with all
applicable regulatory requirements, the results of product
development, nonclinical studies and clinical trials are submitted
to the FDA as part of a BLA requesting approval to market the
product for one or more indications. The BLA must include all
relevant data available from pertinent preclinical and clinical
studies, including negative or ambiguous results as well as
positive findings, together with detailed information relating to
the product’s chemistry, manufacturing, controls, and
proposed labeling, among other things. Data can come from
company-sponsored clinical studies intended to test the safety and
effectiveness of a use of the product, or from a number of
alternative sources, including studies initiated by
investigators.
In most
cases, the submission of a BLA is subject to a substantial
application user fee. Under the goals and policies agreed to by the
FDA under the Prescription Drug User Fee Act, or PDUFA, for
original BLAs, the FDA’s goal is to review the BLA within ten
months after it accepts the application for filing, or, if the
product relates to an unmet medical need in a serious or
life-threatening indication and has received a priority review
designation, six months after the FDA accepts the application for
filing. The FDA does not always meet its PDUFA goal dates, and the
review process is often significantly extended by FDA requests for
additional information or clarification and a sponsor’s
process to respond to such inquiries. This FDA review typically
takes twelve months from the date the BLA is submitted to the FDA
(for a standard review) and eight months from the date the BLA is
submitted (for a priority review) because the FDA has approximately
two months after BLA submission to make a “filing”
decision.
After
filing the marketing application, the FDA reviews a BLA to
determine, among other things, whether a product is safe, pure and
potent and the facility in which it is manufactured, processed,
packed, or held meets standards designed to assure the
product’s continued safety, purity and potency. Before
approving a BLA, the FDA will typically inspect the facility or
facilities where the product is manufactured. The FDA will not
approve a biological product for marketing unless it determines
that the manufacturing processes and facilities are in compliance
with cGMP requirements and adequate to assure consistent production
of the product within required specifications. Additionally, before
approving a BLA, the FDA will typically inspect one or more
clinical sites to assure compliance with GCPs. If the FDA
determines that the data provided in the application, or the
manufacturing process or manufacturing facilities for the product
are not acceptable, it will outline the deficiencies in the
submission and often will request additional testing or
information. Notwithstanding the submission of any requested
additional information, the FDA ultimately may decide that the
application does not satisfy the regulatory criteria for approval.
The FDA also may refer applications for novel biologic candidates
which present difficult questions of safety or efficacy to an
advisory committee, typically a panel that includes clinicians and
other experts, for review, evaluation and a recommendation as to
whether the application should be approved and under what
conditions, if any. The FDA is not bound by recommendations of an
advisory committee, but it considers such recommendations when
making decisions on approval.
After
the FDA evaluates a BLA and conducts inspections of manufacturing
facilities where the biological product and/or its drug substance
will be produced, the FDA may issue an approval letter or a
Complete Response Letter. An approval letter authorizes commercial
marketing of the product with specific prescribing information for
specific indications. A Complete Response Letter indicates that the
review cycle of the application is complete but the application is
not ready for approval. A Complete Response Letter may request
additional information or clarification, including new clinical
studies. The FDA may delay or refuse approval of a BLA if
applicable regulatory criteria are not satisfied, require
additional testing or information and/or require post-marketing
testing and surveillance to monitor safety or efficacy of a
product. If a Complete Response Letter is issued, the applicant may
either resubmit the BLA, addressing all of the deficiencies
identified in the letter, or withdraw the application. Even if such
data and information are submitted, the FDA may decide that the
re-submitted BLA does not satisfy the criteria for
approval.
If a
product receives regulatory approval, such approval is limited to
the conditions of use (e.g., patient population, indication)
described in the application. Further, depending on the specific
risk(s) to be addressed, the FDA may require that
contraindications, warnings or precautions be included in the
product labeling, require that post-approval trials, including
Phase 4 clinical trials, be conducted to further assess a
product’s safety after approval, require testing and
surveillance programs to monitor the product after
commercialization, or impose other conditions, including
distribution and use restrictions or other risk management
mechanisms under a Risk Evaluation and Mitigation Strategy, or
REMS, plan if it determines that a REMS is necessary to ensure that
the benefits of the product outweigh its risks and to assure the
safe use of the biological product, which can materially affect the
potential market and profitability of the product. The REMS plan
could include medication guides, physician communication plans, or
elements to assure safe use, such as restricted distribution
methods, patient registries and other risk minimization tools. The
FDA also may condition approval on, among other things, changes to
proposed labeling or the development of adequate controls and
specifications. Once approved, the FDA may withdraw the product
approval if compliance with pre- and post-marketing regulatory
standards is not maintained or if problems occur after the product
reaches the marketplace. The FDA may prevent or limit further
marketing of a product based on the results of post- marketing
trials or surveillance programs. After approval, some types of
changes to the approved product, such as adding new indications,
manufacturing changes and additional labeling claims, are subject
to further testing requirements and FDA review and
approval.
Expedited
Review and Approval
A
sponsor may seek approval of its product candidate under programs
designed to accelerate the FDA’s review and approval of new
drugs and biological products that meet certain criteria.
Specifically, new drugs and biological products are eligible for
fast track designation if they are intended to treat a serious or
life-threatening condition and demonstrate the potential to address
unmet medical needs for the condition. For a fast track product,
the FDA may consider sections of the BLA for review on a rolling
basis before the complete application is submitted if relevant
criteria are met. A fast track designated product candidate may
also qualify for priority review, under which the FDA sets the
PDUFA target date for FDA action on the BLA at six months after the
FDA accepts the application for filing. Priority review is granted
where there is evidence that the proposed product would be a
significant improvement in the safety or effectiveness of the
treatment, diagnosis, or prevention of a serious condition. If
criteria are not met for priority review, the application is
subject to the standard FDA review period of 10 months after FDA
accepts the application for filing. Priority review designation
does not change the scientific/medical standard for approval or the
quality of evidence necessary to support approval.
Under
the accelerated approval program, the FDA may approve a BLA on the
basis of either a surrogate endpoint that is reasonably likely to
predict a clinical benefit, or on a clinical endpoint that can be
measured earlier than irreversible morbidity or mortality, that is
reasonably likely to predict an effect on irreversible morbidity or
mortality or other clinical benefit, taking into account the
severity, rarity, or prevalence of the condition and the
availability or lack of alternative treatments. Post-marketing
studies or completion of ongoing studies after marketing approval
are generally required to verify the biologic’s clinical
benefit in relationship to the surrogate endpoint or ultimate
outcome in relationship to the clinical benefit. In addition, the
Food and Drug Administration Safety and Innovation Act, or FDASIA,
which was enacted and signed into law in 2012, established the new
Breakthrough Therapy designation. A sponsor may seek FDA
designation of its product candidate as a breakthrough therapy if
the product candidate is intended, alone or in combination with one
or more other drugs or biologics, to treat a serious or
life-threatening disease or condition and preliminary clinical
evidence indicates that the therapy may demonstrate substantial
improvement over existing therapies on one or more clinically
significant endpoints, such as substantial treatment effects
observed early in clinical development. Sponsors may request the
FDA to designate a breakthrough therapy at the time of or any time
after the submission of an IND, but ideally before an end-of-phase
2 meeting with the FDA. If the FDA designates a breakthrough
therapy, it may take actions appropriate to expedite the
development and review of the application, which may include
holding meetings with the sponsor and the review team throughout
the development of the therapy; providing timely advice to, and
interactive communication with, the sponsor regarding the
development of the drug to ensure that the development program to
gather the nonclinical and clinical data necessary for approval is
as efficient as practicable; involving senior managers and
experienced review staff, as appropriate, in a collaborative,
cross-disciplinary review; assigning a cross-disciplinary project
lead for the FDA review team to facilitate an efficient review of
the development program and to serve as a scientific liaison
between the review team and the sponsor; and considering
alternative clinical trial designs when scientifically appropriate,
which may result in smaller trials or more efficient trials that
require less time to complete and may minimize the number of
patients exposed to a potentially less efficacious
treatment.
Fast Track
designation, priority review and breakthrough therapy designation
do not change the standards for approval but may expedite the
development or approval process.
Post-Approval
Requirements
All
therapeutic products manufactured or distributed pursuant to FDA
approval or licensure are subject to pervasive and continuing
regulation by the FDA, including, among other things, requirements
relating to record-keeping, reporting of adverse experiences,
periodic reporting, product sampling and distribution, and
advertising and promotion of the product. After approval, most
changes to the approved product, such as adding new indications or
other labeling claims, are subject to prior FDA review and
approval. There also are continuing, annual user fee requirements
under PDUFA for any marketed products and the establishments at
which such products are manufactured, as well as new application
fees for supplemental applications containing clinical data.
Biologic manufacturers and their subcontractors are required to
register their establishments with the FDA and certain state
agencies, and are subject to periodic unannounced inspections by
the FDA and certain state agencies for compliance with cGMP
requirements, which impose significant procedural and documentation
requirements. Changes to the manufacturing process are strictly
regulated, and, depending on the significance of the change, may
require prior FDA approval before being implemented. FDA
regulations also require investigation and correction of any
deviations from cGMP and impose reporting requirements on
manufacturers. Accordingly, manufacturers must continue to expend
time, money and effort in the area of production and quality
control to maintain compliance with cGMP and other aspects of
regulatory compliance. CEL-SCI cannot be certain that it, or
CEL-SCI’s present or future suppliers, will be able to comply
with the cGMP regulations and other FDA regulatory requirements. If
CEL-SCI is not able to comply with these requirements, the FDA may,
among other things, take enforcement action or seek sanctions
against use, impose restrictions on a product or its manufacturer,
require us to recall a product from distribution, or withdraw
approval of the BLA.
The FDA
may withdraw approval if compliance with regulatory requirements
and standards is not maintained or if problems occur after the
product reaches the market. Later discovery of previously unknown
problems with a product, including adverse events of unanticipated
severity or frequency, or with manufacturing processes, or failure
to comply with regulatory requirements, may result in revisions to
the approved labeling to add new safety information; imposition of
post-market studies or clinical studies to assess new safety risks;
or imposition of distribution restrictions or other restrictions
under a REMS program. Other potential consequences include, among
other things:
●
restrictions on the
marketing or manufacturing of the product, complete withdrawal of
the product from the market or product recalls;
●
fines, warning
letters or holds on post-approval clinical studies;
●
refusal of the FDA
to approve pending applications or supplements to approved
applications, or suspension or revocation of product license
approvals;
●
product seizure or
detention, or refusal to permit the import or export of
products;
●
injunctions or the
imposition of civil or criminal penalties; and
●
consent decrees,
corporate integrity agreements, debarment, or exclusion from
federal healthcare programs; or mandated modification of
promotional materials and labeling and the issuance of corrective
information.
The FDA
closely regulates the marketing, labeling, advertising and
promotion of drugs and biologics. A company can make only those
claims relating to safety and efficacy, purity and potency that are
approved by the FDA and in accordance with the provisions of the
approved label. The FDA and other agencies actively enforce the
laws and regulations prohibiting the promotion of unapproved, or
“off-label,” uses. Failure to comply with these
requirements can result in, among other things, adverse publicity,
warning letters, corrective advertising and potential civil and
criminal penalties. Physicians may prescribe legally available
products for uses that are not described in the product’s
labeling and that differ from those tested by us and approved by
the FDA. Such off-label uses are common across medical specialties.
Physicians may believe that such off-label uses are the best
treatment for many patients in varied circumstances. The FDA does
not regulate the behavior of physicians in their choice of
treatments. The FDA does, however, restrict manufacturer’s
communications on the subject of off-label use of their
products.
Orphan
Drug Designation
Under
the Orphan Drug Act, the FDA may grant orphan drug designation to
drugs or biologics intended to treat a rare disease or condition
that affects fewer than 200,000 individuals in the United States,
or if it affects more than 200,000 individuals in the United
States, there is no reasonable expectation that the cost of
developing and making the drug for this type of disease or
condition will be recovered from sales in the United
States.
In the
United States, orphan drug designation entitles a party to
financial incentives such as opportunities for grant funding
towards clinical trial costs, tax advantages and user-fee waivers.
In addition, if a product receives the first FDA approval for the
indication for which it has orphan designation, the product is
entitled to orphan drug exclusivity, which means the FDA may not
approve any other application to market the same drug for the same
indication for a period of 7 years, except in limited
circumstances, such as a showing of clinical superiority over the
product with orphan exclusivity. Orphan drug exclusivity also could
block the approval of one of CEL-SCI’s products for seven
years if a competitor obtains approval of the same product before
CEL-SCI does, as defined by the FDA, for the same indication
CEL-SCI is seeking, or if CEL-SCI’s product candidate is
determined to be contained within the scope of the
competitor’s product for the same indication or disease. If
one of CEL-SCI’s products designated as an orphan drug
receives marketing approval for an indication broader than that
which is designated, it may not be entitled to orphan drug
exclusivity. Orphan drug status in the European Union has similar,
but not identical, requirements and benefits.
Orphan
drug designation must be requested before submitting a BLA to the
FDA for review and approval. After the FDA grants orphan drug
designation, the identity of the therapeutic agent and its
potential orphan use are disclosed publicly by the FDA. Orphan drug
designation does not convey any advantage in, or shorten the
duration of, the regulatory review and approval
process.
Other U.S. Health Care Laws
CEL-SCI’s
sales, promotion, medical education and other activities following
product approval will be subject to regulation by numerous
regulatory and law enforcement authorities in the United States in
addition to the FDA, including potentially the Federal Trade
Commission, the Department of Justice, the Centers for Medicare and
Medicaid Services, other divisions of the Department of Health and
Human Services and state and local governments. CEL-SCI’s
promotional and scientific/educational programs must comply with
the anti-kickback provisions of the Social Security Act, the
Foreign Corrupt Practices Act, the False Claims Act, the Physician
Payments Sunshine Act, the Veterans Health Care Act and similar
state laws.
Depending on the
circumstances, failure to meet these applicable regulatory
requirements can result in criminal prosecution, fines or other
penalties, exclusion from government health care programs,
injunctions, recall or seizure of products, total or partial
suspension of production, denial or withdrawal of pre-marketing
product approvals, private “qui tam” actions brought by
individual whistleblowers under the False Claims Act in the name of
the government or refusal to allow us to enter into supply
contracts, including government contracts.
Coverage, Pricing and Reimbursement in the U.S.
Sales
of pharmaceutical products depend significantly on the availability
of third-party coverage and reimbursement. Third-party payors
include government health administrative authorities, managed care
providers, private health insurers and other organizations. These
third-party payors are increasingly challenging the price and
examining the cost-effectiveness of medical products and services.
In addition, significant uncertainty exists as to the reimbursement
status of newly approved healthcare products and new drug classes,
including biological products such as CEL-SCI’s product
candidates. CEL-SCI may need to conduct expensive clinical studies
to demonstrate the comparative cost-effectiveness of its products.
The product candidates that CEL-SCI develops may not be considered
cost-effective. It is time consuming and expensive for us to seek
reimbursement from third- party payors. Reimbursement may not be
available or sufficient to allow CEL-SCI to sell its products on a
competitive and profitable basis.
The
United States and some foreign jurisdictions are considering or
have enacted a number of legislative and regulatory proposals to
change the healthcare system in ways that could affect
CEL-SCI’s ability to sell its products profitably. Among
policy makers and payors in the United States and elsewhere, there
is significant interest in promoting changes in healthcare systems
with the stated goals of containing healthcare costs, improving
quality and/or expanding access. In the United States, the
pharmaceutical industry has been a particular focus of these
efforts and has been significantly affected by major legislative
initiatives.
Foreign Regulation
In
addition to regulations in the United States, CEL-SCI will be
subject to a variety of foreign regulations governing clinical
trials and commercial sales and distribution of its products to the
extent CEL-SCI chooses to develop or sell any products outside of
the United States. The approval process varies from country to
country and the time may be longer or shorter than that required to
obtain FDA approval. The requirements governing the conduct of
clinical trials, product licensing, pricing and reimbursement vary
greatly from country to country.
The
risks described below could adversely affect the price of
CEL-SCI’s common stock.
Risks Related to CEL-SCI
CEL-SCI has incurred significant losses since inception, and
CEL-SCI anticipates that it will continue to incur significant
losses for the foreseeable future and may never achieve or maintain
profitability.
CEL-SCI
has a history of net losses, expects to incur substantial losses
and have negative operating cash flow for the foreseeable future,
and may never achieve or maintain profitability. Since
the date of its formation and through September 30, 2019, CEL-SCI
incurred net losses of approximately $354 million. CEL-SCI has
relied principally upon the proceeds from the public and private
sales of its securities to finance its activities to date. To date,
CEL-SCI has not commercialized any products or generated any
revenue from the sale of products, and CEL-SCI does not expect to
generate any product revenue for the foreseeable future. CEL-SCI
does not know whether or when it will generate product revenue or
become profitable.
CEL-SCI
is heavily dependent on the success of Multikine which is under
clinical development. CEL-SCI cannot be certain that Multikine will
receive regulatory approval or be successfully commercialized even
if CEL-SCI receives regulatory approval. Multikine is the only
product candidate in late-stage clinical development, and
CEL-SCI’s business currently depends heavily on its
successful development, regulatory approval and commercialization.
CEL-SCI has no drug products for sale currently and may never be
able to develop approved and marketable drug products.
Even
if CEL-SCI succeeds in developing and commercializing one or more
of its product candidates, CEL-SCI expects to continue to incur
significant operating and capital expenditures as
CEL-SCI:
●
continues
to undertake preclinical development and clinical trials for
product candidates;
●
seeks
regulatory approvals for product candidates; and
●
implements
additional internal systems and infrastructure.
To
become and remain profitable, CEL-SCI must succeed in developing
and commercializing product candidates which must generate
significant revenue. This will require CEL-SCI to be successful in
a range of challenging activities, including completing preclinical
testing and clinical trials of its product candidates, discovering
or acquiring additional product candidates, obtaining regulatory
approval for these product candidates and manufacturing, marketing
and selling any products for which CEL-SCI may obtain regulatory
approval. CEL-SCI is only in the preliminary stages of most of
these activities. CEL-SCI may never succeed in these activities
and, even if CEL-SCI does, may never generate revenue that is
significant enough to achieve profitability.
Even
if CEL-SCI does achieve profitability, it may not be able to
sustain or increase profitability on a quarterly or annual basis.
The failure to become and remain profitable could depress the value
of CEL-SCI and could impair its ability to raise capital, expand
its business, maintain research and development efforts, diversify
product offerings or even continue in operation. A decline in the
value of CEL-SCI could cause its stockholders to lose all or part
of their investment.
CEL-SCI’s financial statements include an explanatory
paragraph that expresses substantial doubt about its ability to
continue as a going concern, indicating the possibility that
CEL-SCI may not be able to operate in the future.
Primarily
as a result of CEL-SCI’s losses incurred to date,
CEL-SCI’s expected continued future losses, and limited cash
balances, CEL-SCI has included an explanatory paragraph in its
financial statements expressing substantial doubt about its ability
to continue as a going concern. CEL-SCI has included such an
explanatory paragraph on numerous occasions in the preceding years.
CEL-SCI’s ability to continue as a going concern is
contingent upon, among other factors, the sale of the shares of its
common stock or obtaining alternate financing.
CEL-SCI’s Independent Registered Public Accountants have
included in their report on CEL-SCI’s financial statements a
paragraph stating that we may be unable to continue as a going
concern.
As
a result of CEL-SCI’s recurring losses from operations,
CEL-SCI’s independent registered public accounting firm, BDO
USA, LLP, has issued a report in connection with their audit of
CEL-SCI’s financial statements for the year ended September
30, 2019, that included an explanatory paragraph referring to
CEL-SCI’s recurring losses from operations and expressing
substantial doubt in CEL-SCI’s ability to continue as a going
concern without additional capital becoming available. The doubt
about CEL-SCI’s ability to continue as a going concern could
have an adverse impact on CEL-SCI’s ability to execute
CEL-SCI’s business plan, result in the reluctance on the part
of certain suppliers to do business with CEL-SCI, or adversely
affect CEL-SCI’s ability to raise additional debt or equity
capital.
CEL-SCI will require substantial additional capital to remain in
operation. A failure to obtain this necessary capital when needed
could force CEL-SCI to delay, limit, reduce or terminate the
product candidates’ development or commercialization
efforts.
As
of September 30, 2019, CEL-SCI had cash and cash equivalents of
approximately $8.4 million. CEL-SCI believes that it
will continue to expend substantial resources for the foreseeable
future developing Multikine, LEAPS and any other product candidates
or technologies that it may develop or acquire. These expenditures
will include costs associated with research and development,
potentially obtaining regulatory approvals and having the products
manufactured, as well as marketing and selling products approved
for sale, if any. In addition, other unanticipated costs may arise.
Because the outcome of the current and anticipated clinical trials
is highly uncertain, CEL-SCI cannot reasonably estimate the actual
amounts necessary to successfully complete the development and
commercialization of the product candidates.
CEL-SCI’s
future capital requirements depend on many factors,
including:
●
the
rate of progress of, results of and cost of completing Phase 3
clinical development of Multikine for the treatment of certain head
and neck cancers;
●
the
results of the applications to and meetings with the FDA, the EMA
and other regulatory authorities and the consequential effect on
operating costs;
●
assuming
favorable Phase 3 clinical results, the cost, timing and outcome of
the efforts to obtain marketing approval for Multikine in the
United States, Europe and in other jurisdictions, including the
preparation and filing of regulatory submissions for Multikine with
the FDA, the EMA and other regulatory authorities;
●
the
scope, progress, results and costs of additional preclinical,
clinical, or other studies for additional indications for
Multikine, LEAPS and other product candidates and technologies that
CEL-SCI may develop or acquire;
●
the
timing of, and the costs involved in, obtaining regulatory
approvals for LEAPS if clinical studies are
successful;
●
the
cost and timing of future commercialization activities for the
products, if any of the product candidates are approved for
marketing, including product manufacturing, marketing, sales and
distribution costs;
●
the
revenue, if any, received from commercial sales of the product
candidates for which CEL-SCI receives marketing
approval;
●
the
cost of having the product candidates manufactured for clinical
trials and in preparation for commercialization;
●
the
ability to establish and maintain strategic collaborations,
licensing or other arrangements and the financial terms of such
agreements;
●
the
costs involved in preparing, filing and prosecuting patent
applications and maintaining, defending and enforcing its
intellectual property rights, including litigation costs, and the
outcome of such litigation; and
●
the
extent to which CEL-SCI acquires or in-licenses other products or
technologies.
CEL-SCI
will need to raise additional funds in order to continue its
operations and additional funds may not be available when CEL-SCI
needs them on terms that are acceptable to CEL-SCI, or at all. If
adequate funds are not available to CEL-SCI on a timely basis,
CEL-SCI may be required to delay, limit, reduce or terminate
preclinical studies, clinical trials or other development
activities for Multikine, LEAPS, or any other product candidates or
technologies that CEL-SCI develops or acquires, or delay, limit,
reduce or terminate its sales and marketing capabilities or other
activities that may be necessary to commercialize its product
candidates. Due to recurring losses from operations and future
liquidity needs, there is substantial doubt about CEL-SCI’s
ability to continue as a going concern without additional capital
becoming available. The doubt about CEL-SCI’s ability to
continue as a going concern could have an adverse impact on
CEL-SCI’s ability to execute its business plan, result in the
reluctance on the part of certain suppliers to do business with
CEL-SCI, or adversely affect CEL-SCI’s ability to raise
additional debt or equity capital.
The costs of the product candidates development and clinical trials
are difficult to estimate and will be very high for many years,
preventing CEL-SCI from making a profit for the foreseeable future,
if ever.
Clinical
and other studies necessary to obtain approval of a new drug or
biologic can be time consuming and costly, especially in the United
States, but also in foreign countries. The estimates of the costs
associated with future clinical trials and research may be
substantially lower than what CEL-SCI actually experiences. It is
impossible to predict what CEL-SCI will face in the development of
a complex product candidate, such as Multikine. The purpose of
clinical trials is to provide both CEL-SCI and regulatory
authorities with safety and efficacy data in humans. The difficult
and often complex steps necessary to obtain regulatory approval,
especially that of the FDA and the EMA, involve significant costs
and may require several years to complete. CEL-SCI expects that it
will need substantial additional financing over an extended period
of time in order to fund the costs of future clinical trials,
related research, and general and administrative
expenses.
The extent of the clinical trials and research programs are
primarily based upon the amount of capital available to CEL-SCI and
the extent to which CEL-SCI receives regulatory approvals for
clinical trials. CEL-SCI has established estimates of the future
costs of the Phase 3 clinical trial for Multikine, but, as
explained above, the estimates may not prove correct.
Completion of modifications to its manufacturing facility may delay
submission of CEL-SCI’s Biologics License Application to the
FDA with respect to Multikine as a neoadjuvant treatment of
advanced head and neck cancer.
If
CEL-SCI’s ongoing Phase 3 clinical trial is successful, some
modifications to CEL-SCI’s manufacturing facility will have
to be made in order to prepare the facility to produce Multikine
for commercial purposes and before CEL-SCI’s Biologics
License Application (BLA) can be approved by the FDA. Although
these modifications are in process, they may not be completed prior
to the time CEL-SCI’s Phase 3 clinical trial ends, the BLA is
submitted and the FDA would seek to conduct a pre-approval
inspection of the manufacturing facility and its processes. In that
case, and assuming a positive outcome for CEL-SCI’s Phase 3
clinical trial, submission of CEL-SCI’s marketing application
to the FDA and/or the approval of such a BLA for Multikine as a
treatment for advanced head and neck cancer may be
delayed.
An adverse determination in any future legal proceedings could have
a material adverse effect on CEL-SCI.
CEL-SCI
may be the target of claims asserting violations of securities
fraud and derivative actions, or other litigation or arbitration
proceedings in the future. Any future litigation could result in
substantial costs and divert management’s attention and
resources. These legal proceedings may result in large judgments or
settlements against CEL-SCI, any of which could have a material
adverse effect on its business, operating results, financial
condition and liquidity.
Compliance with changing regulations concerning corporate
governance and public disclosure may result in additional
expenses.
Changing
laws, regulations and standards relating to corporate governance
and public disclosure may create uncertainty regarding compliance
matters. New or changed laws, regulations and standards are subject
to varying interpretations in many cases. As a result, their
application in practice may evolve over time. CEL-SCI is committed
to maintaining high standards of corporate governance and public
disclosure. Complying with evolving interpretations of new or
changing legal requirements may cause CEL-SCI to incur higher costs
as CEL-SCI revises current practices, policies and procedures, and
may divert management time and attention from potential
revenue-generating activities to compliance matters. If the efforts
to comply with new or changed laws, regulations and standards
differ from the activities intended by regulatory or governing
bodies due to ambiguities related to practice, CEL-SCI’s
reputation may also be harmed. Further, CEL-SCI’s board
members, chief executive officer, and other executive officers
could face an increased risk of personal liability in connection
with the performance of their duties. As a result, CEL-SCI may have
difficulty attracting and retaining qualified board members and
executive officers, which could harm its business.
CEL-SCI has not established a definite plan for the marketing of
Multikine, if approved.
CEL-SCI
has not established a definitive plan for marketing nor has CEL-SCI
established a price structure for any of its product candidates, if
approved. However, CEL-SCI intends, if it is in a position to do
so, to sell Multikine itself in certain markets where it is
approved, and or to enter into written marketing agreements with
various third parties with established sales forces in such
markets. The sales forces in turn would, CEL-SCI
believes, focus on selling Multikine to targeted cancer centers,
physicians and clinics involved in the treatment of head and neck
cancer. CEL-SCI has already licensed future sales of Multikine, if
approved, to three companies: Teva Pharmaceutical Industries Ltd.
in Israel, Turkey, Serbia and Croatia; Orient Europharma in Taiwan,
Singapore, Hong Kong, Malaysia, South Korea, the Philippines,
Australia and New Zealand; and Byron BioPharma, LLC in South
Africa. CEL-SCI believes that these companies will have
the resources to market Multikine appropriately in their respective
territories, if approved, but there is no guarantee that they
will. There is no assurance that CEL-SCI will be able to
find qualified third-party partners to market its products in other
areas, on terms that are favorable to CEL-SCI, or at
all.
CEL-SCI
may encounter problems, delays and additional expenses in
developing marketing plans with third parties. In addition, even if
Multikine, if approved, is cost-effective and demonstrated to
increase overall patient survival, CEL-SCI may experience other
limitations involving the proposed sale of Multikine, such as
uncertainty of third-party coverage and reimbursement. There is no
assurance that CEL-SCI can successfully market Multikine, if
approved, or any other product candidates it may
develop.
CEL-SCI hopes to expand its clinical development capabilities in
the future, and any difficulties hiring or retaining key personnel
or managing this growth could disrupt its operations.
CEL-SCI
is highly dependent on the principal members of its management and
development staff. If the Phase 3 clinical trial is successful,
CEL-SCI expects to expand its clinical development and
manufacturing capabilities, which will involve hiring additional
employees. Future growth will require CEL-SCI to continue to
implement and improve its managerial, operational and financial
systems and continue to retain, recruit and train additional
qualified personnel, which may impose a strain on its
administrative and its operational infrastructure. The competition
for qualified personnel in the biopharmaceutical field is intense.
CEL-SCI is highly dependent on its ability to attract, retain and
motivate highly qualified management and specialized personnel
required for clinical development. Due to limited resources,
CEL-SCI may not be able to manage effectively the expansion of its
operations or recruit and train additional qualified
personnel. If CEL-SCI is unable to retain key personnel
or manage its future growth effectively, CEL-SCI may not be able to
implement its business plan.
If product liability or patient injury lawsuits are brought against
CEL-SCI, CEL-SCI may incur substantial liabilities and may be
required to limit clinical testing or future commercialization of
Multikine or its other product candidates.
CEL-SCI
faces an inherent risk of product liability as a result of the
clinical testing of Multikine and other product candidates, and
will face an even greater risk if CEL-SCI is able to commercialize
any of its product candidates. For example, CEL-SCI may be sued if
its Multikine or LEAPS product candidates, or any other future
product candidates, allegedly cause injury or are found to be
otherwise unsuitable during clinical testing, manufacturing or, if
approved, marketing, sale or administration to patients. Any such
product liability claims may include allegations of defects in
manufacturing, defects in design, a failure to warn of dangers
inherent in the product candidate, negligence, strict liability and
a breach of warranties. Claims could also be asserted under state
consumer protection acts.
Furthermore,
Multikine is made, in part, from components of human blood. There
are inherent risks associated with products that involve human
blood such as possible contamination with viruses, including
hepatitis or HIV. Any possible contamination could cause injuries
to patients who receive contaminated Multikine, or could require
CEL-SCI to destroy batches of Multikine, thereby subjecting CEL-SCI
to possible financial losses, lawsuits and harm to its
business.
If
CEL-SCI cannot successfully defend itself against product liability
claims, CEL-SCI may incur substantial liabilities or be required to
limit or cease the clinical testing or commercialization of its
product candidates, if approved. Even a successful defense would
require significant financial and management resources. Regardless
of the merits or eventual outcome, liability claims may result
in:
●
decreased
demand for Multikine or other product candidates, if approved and
commercialized, or clinical holds or suspension of the IND while
the candidates are still in clinical development;
●
injury
to CEL-SCI’s reputation;
●
withdrawal
of existing, or failure to enroll additional, clinical trial
participants;
●
costs
to defend any related litigation;
●
a
diversion of management’s time and resources;
●
substantial
monetary awards to trial participants or patients;
●
recalls
of approved products, withdrawal of BLA approvals or new labeling,
marketing or promotional restrictions;
●
inability
to commercialize Multikine or other product candidates;
and
●
a
decline in the price of CEL-SCI’s common stock.
Although
CEL-SCI has product liability insurance for Multikine in the amount
of $10 million, the successful prosecution of a product liability
case against CEL-SCI could have a materially adverse effect upon
its business if the amount of any judgment exceeds the insurance
coverage. Any claim that may be brought against CEL-SCI could
result in a court judgment or settlement in an amount that is not
covered, in whole or in part, by CEL-SCI’s insurance or that
is in excess of the limits of the insurance coverage.
CEL-SCI’s insurance policies also have various exclusions,
and CEL-SCI may be subject to a claim for which CEL-SCI has no
coverage. CEL-SCI may have to pay any amounts awarded by a court or
negotiated in a settlement that exceed the coverage limitations or
that are not covered by its insurance, and CEL-SCI may not have, or
be able to obtain, sufficient capital to pay such
amounts. CEL-SCI commenced the Phase 3 clinical trial
for Multikine in December 2010. Although no claims have been
brought to date, participants in the clinical trials could bring
civil actions against CEL-SCI for any unanticipated harmful effects
allegedly arising from the use of Multikine or any other product
candidate that CEL-SCI may attempt to develop.
CEL-SCI’s commercial success depends, in part, upon attaining
significant market acceptance of its product candidates, if
approved, among physicians, patients, healthcare payors and major
operators of cancer clinics.
Even
if CEL-SCI obtains regulatory approval for its product candidates,
any resulting product may not gain market acceptance among
physicians, healthcare payors, patients and the medical community,
which are critical to commercial success. Market acceptance of any
product candidate for which CEL-SCI receives approval depends on a
number of factors, including:
●
the
efficacy and safety of the products as demonstrated in clinical
trials;
●
the
timing of market introduction of such product as well as
competitive products;
●
the
clinical indications for which the biological product is
approved;
●
the
approval, availability, market acceptance and reimbursement for the
companion diagnostic, if appropriate or necessary;
●
acceptance
by physicians, major operators of cancer clinics and patients of
the biologic as a safe and effective treatment;
●
the
potential and perceived advantages of such product candidate over
alternative treatments, especially with respect to patient subsets
that are targeted with such product;
●
the
safety of such product seen in a broader patient group, including
its use outside the approved indications;
●
the
cost of treatment in relation to alternative
treatments;
●
the
availability of adequate reimbursement and pricing by third-party
payors and government authorities;
●
relative
convenience and ease of administration;
●
the
prevalence and severity of adverse side effects; and
●
the
effectiveness of sales and marketing efforts.
If
CEL-SCI’s product candidates are approved, but fail to
achieve an adequate level of acceptance by physicians, healthcare
payors and patients, CEL-SCI will not be able to generate
significant revenues, and CEL-SCI may not become or remain
profitable.
CEL-SCI’s ability to utilize its net operating loss
carryforwards and certain other tax attributes may be
limited.
Under
Section 382 of the Internal Revenue Code of 1986, as amended, if a
corporation undergoes an “ownership change” (generally
defined as a greater than 50% change (by value) in CEL-SCI’s
equity ownership over a three-year period), the corporation’s
ability to use its pre-change net operating loss carryforwards and
other pre-change tax attributes to offset its post-change income
may be limited. As a result of public offerings and other
transactions, CEL-SCI may experience ownership changes in the
future based on subsequent shifts in its stock ownership, some of
which are outside its control. As a result, the ability to use the
pre-change net operating loss carryforwards and other pre-change
tax attributes to offset U.S. federal taxable income may be subject
to limitations, which could result in increased tax liability to
CEL-SCI.
Under CEL-SCI’s amended bylaws, stockholders that initiate
certain proceedings may be obligated to reimburse CEL-SCI and its
officers and directors for all fees, costs and expenses incurred in
connection with such proceedings if the claim proves
unsuccessful.
On
February 18, 2015, CEL-SCI adopted new bylaws which include a
fee-shifting provision in Article X for stockholder claims. Article
X provides that in the event any stockholder initiates or asserts a
claim against CEL-SCI, or any of its officers or directors,
including any derivative claim or claim purportedly filed on
CEL-SCI’s behalf, and the stockholder does not obtain a
judgment on the merits that substantially achieves, in substance
and amount, the full remedy sought, then the stockholder will be
obligated to reimburse CEL-SCI and any of its officers or directors
named in the action, for all fees, costs and expenses of every kind
and description that CEL-SCI or its officers or directors may incur
in connection with the claim. In adopting Article X, it is the
intent that:
●
all
actions, including federal securities law claims, would be subject
to Article X;
●
the
phrase “a judgment on the merits” means the
determination by a court of competent jurisdiction on the matters
submitted to the court;
●
the
phrase “substantially achieves, in both substance and
amount” means the plaintiffs in the action would be awarded
at least 90% of the relief sought;
●
only
persons who were stockholders at the time an action was brought
would be subject to Article X; and
●
only
the directors or officers named in the action would be allowed to
recover.
The
fee-shifting provision contained in Article X of the bylaws is not
limited to specific types of actions, but is rather potentially
applicable to the fullest extent permitted by law. Fee-shifting
bylaws are relatively new and untested. The case law and potential
legislative action on fee-shifting bylaws are evolving and there
exists considerable uncertainty regarding the validity of, and
potential judicial and legislative responses to, such bylaws. For
example, it is unclear whether the ability to invoke the
fee-shifting bylaw in connection with claims under the federal
securities laws would be pre-empted by federal law. Similarly, it
is unclear how courts might apply the standard that a claiming
stockholder must obtain a judgment that substantially achieves, in
substance and amount, the full remedy sought. The application of
the fee-shifting bylaw in connection with such claims, if any, will
depend in part on future developments of the law. CEL-SCI cannot
assure its shareholders that CEL-SCI will or will not invoke the
fee-shifting bylaw in any particular dispute. In addition, given
the unsettled state of the law related to fee-shifting bylaws, such
as CEL-SCI’s, CEL-SCI may incur significant additional costs
associated with resolving disputes with respect to such bylaw,
which could adversely affect CEL-SCI’s business and financial
condition.
If
a stockholder that brings any such claim, suit, action or
proceeding is unable to obtain the required judgment, the
attorneys’ fees and other litigation expenses that might be
shifted to a claiming stockholder are potentially significant. This
fee-shifting bylaw may therefore dissuade or discourage
stockholders and their attorneys from initiating lawsuits or claims
against CEL-SCI or its directors and officers. In addition, it may
impact the fees, contingency or otherwise, required by potential
plaintiffs’ attorneys to represent the stockholders or
otherwise discourage plaintiffs’ attorneys from representing
the stockholders at all. As a result, this bylaw may limit the
ability of stockholders to affect CEL-SCI’s management and
direction, particularly through litigation or the threat of
litigation.
The provision of the amended bylaws requiring exclusive venue in
the U.S. District Court for Delaware for certain types of lawsuits
may have the effect of discouraging lawsuits against CEL-SCI and
its directors and officers.
Article
X of CEL-SCI’s amended bylaws provides that stockholder
claims brought against CEL-SCI, or its officers or directors,
including any derivative claim or claim purportedly filed on its
behalf, must be brought in the U.S. District Court for the district
of Delaware and that with respect to any such claim, the laws of
Delaware will apply.
The
exclusive forum provision may limit a stockholder’s ability
to bring a claim in a judicial forum the stockholder finds
favorable for disputes with CEL-SCI or its directors or officers,
and may have the effect of discouraging lawsuits with respect to
claims that may benefit CEL-SCI or its stockholders.
Risks Related to Clinical Development, Government Approvals and the
Marketing of Biopharmaceutical Products
CEL-SCI depends heavily on the success of Multikine, which is in
Phase 3 clinical development, while our other candidates are still
in preclinical phases. CEL-SCI’s product candidates must
undergo rigorous preclinical and clinical testing and regulatory
approvals, which could be costly and time-consuming and subject
CEL-SCI to unanticipated delays or prevent CEL-SCI from marketing
any products. If CEL-SCI is unable to advance its product
candidates in clinical development, obtain regulatory approval and
ultimately commercialize its product candidates, or experience
significant delays in doing so, CEL-SCI’s business will be
materially harmed.
CEL-SCI
currently has no products approved for sale and CEL-SCI cannot
guarantee that it will ever have marketable products.
CEL-SCI’s product candidates are subject to premarket
approval from the FDA in the United States, the EMA in the European
Union, and by comparable agencies in most foreign countries before
they can be sold. Before obtaining marketing approval, these
product candidates must undergo costly and time consuming
preclinical and clinical testing which could subject CEL-SCI to
unanticipated delays and may prevent CEL-SCI from marketing the
product candidates in the future. There can be no assurance that
such approvals will be granted on a timely basis, if at
all.
Clinical
testing is expensive and can take many years to complete, and its
outcome is inherently uncertain. Failure can occur at any time
during the clinical trial process. The results of preclinical
studies and early clinical trials of the product candidates may not
be predictive of the results of later-stage clinical trials. A
number of companies in the biopharmaceutical industry have suffered
significant setbacks in advanced clinical trials due to lack of
efficacy or adverse safety profiles, notwithstanding promising
results in earlier trials. CEL-SCI’s current and future
clinical trials may not be successful.
Although CEL-SCI is no longer treating patients and simply
following the patients per the protocol of the Phase 3 clinical
trial for its lead investigational product Multikine, CEL-SCI may
experience delays in completion of this clinical trial and CEL-SCI
does not know whether the clinical trial will need to be
redesigned. In addition, CEL-SCI is in the early development stages
for the candidates designed using its LEAPS technology and have not
yet initiated any clinical studies for any of those product
candidates. Clinical trials can be delayed for a variety of
reasons, including delays related to:
●
the
availability of financial resources needed to commence and complete
the planned trials;
●
obtaining
regulatory approval to commence a trial;
●
reaching
agreement on acceptable terms with prospective contract research
organizations, or CROs, and clinical trial sites, the terms of
which can be subject to extensive negotiation and may vary
significantly among different CROs and trial sites;
●
obtaining
Institutional Review Board, or IRB, approval at each clinical trial
site;
●
recruiting
suitable patients to participate in a trial;
●
having
patients complete a trial or return for post-treatment
follow-up;
●
clinical
trial sites deviating from trial protocol or dropping out of a
trial;
●
adding
new clinical trial sites; or
●
manufacturing
sufficient quantities of the product candidate for use in clinical
trials.
Patient
enrollment, a significant factor in the timing of clinical trials,
is affected by many factors including the competence of the CRO
running the study, size and nature of the patient population, the
proximity of patients to clinical sites, the eligibility criteria
for the trial, the design of the clinical trial, competing clinical
trials and clinicians' and patients’ perceptions as to the
potential advantages of the drug being studied in relation to other
available therapies, including any new drugs that may be approved
for the indications CEL-SCI is investigating. Furthermore, CEL-SCI
relies on CROs and clinical trial sites to ensure the proper and
timely conduct of the clinical trials and while CEL-SCI has
agreements governing their committed activities, CEL-SCI has
limited influence over their actual performance.
CEL-SCI could also encounter significant delays
and/or need to terminate a development program for a product
candidate if physicians encounter unresolved ethical issues
associated with enrolling patients in clinical trials of the
product candidates while existing treatments have established
safety and efficacy profiles. Further, a clinical trial may be
suspended or terminated by CEL-SCI, one or more of the IRBs for the
institutions in which such trials are being conducted, by CEL-SCI
upon a final recommendation by the Independent Data Monitoring
Committee, or IDMC, with which CEL-SCI agrees for such trial, or by
FDA or other regulatory authorities due to a number of factors,
including failure to conduct the clinical trial in accordance with
regulatory requirements or the clinical protocols, as a result of
inspection of the clinical trial operations or trial site(s) by FDA
or other regulatory authorities, the imposition of a clinical
hold or partial clinical hold, unforeseen safety issues
or adverse side effects, failure to demonstrate a benefit from
using a product candidate, changes in governmental regulations or
administrative actions or lack of adequate funding to continue the
clinical trial. The occurrence of any one or more of these events
would have significant and severe material consequences for CEL-SCI
and could impact CEL-SCI’s ability to continue as a going
concern.
If
CEL-SCI experiences termination of, or delays in the completion of,
any clinical trial of its product candidates, the commercial
prospects for the product candidates will be harmed, and the
ability to generate product revenues will be delayed. In addition,
any delays in completing the clinical trials will increase the
costs, slow the product development and approval process and
jeopardize the ability to commence product sales and generate
revenues. Any of these occurrences may harm CEL-SCI’s
business, prospects, financial condition and results of operations
significantly. Many of the factors that cause, or lead to, a delay
in the commencement or completion of clinical trials may also
ultimately lead to a delay or the denial of regulatory approval for
the product candidates.
CEL-SCI
cannot be certain when or under what conditions it will undertake
future clinical trials. A variety of issues may delay
the ongoing Phase 3 clinical trial for Multikine for advanced head
and neck cancer. Early trials for the other product candidates, or
the plans for later trials, may not satisfy the requirements of
regulatory authorities, such as the FDA. CEL-SCI may fail to find
subjects willing to enroll in the trials. Accordingly, the clinical
trials relating to the product candidates may not be completed on
schedule, the FDA or foreign regulatory agencies may order CEL-SCI
to stop or modify research, or these agencies may not ultimately
approve any of the product candidates for commercial sale. Varying
interpretations of the data obtained from pre-clinical and clinical
testing could delay, limit or prevent regulatory approval of the
product candidates. The data collected from the clinical trials may
not be sufficient to support regulatory approval of the various
product candidates, including Multikine. The failure to adequately
demonstrate the safety and efficacy of any of the product
candidates would delay or prevent regulatory approval of the
product candidates in the United States, which could prevent
CEL-SCI from achieving profitability. Although CEL-SCI had positive
results in the Phase 2 trials for Multikine, those results were for
a very small sample set, and CEL-SCI will not know how Multikine
will perform in a larger set of subjects until CEL-SCI completes
the Phase 3 clinical trial.
The
development and testing of product candidates and the process of
obtaining regulatory approvals and the subsequent compliance with
appropriate federal, state, local and foreign statutes and
regulations require the expenditure of substantial time and
financial resources. Failure to comply with the
applicable U.S. requirements at any time during the product
development process, approval process or after approval, may
subject an applicant to administrative or judicial sanctions. FDA
sanctions could include, among other actions, refusal to approve
pending applications, withdrawal of an approval, a clinical hold,
termination of the Phase 3 study, warning letters, product recalls
or withdrawals from the market, product seizures, total or partial
suspension of production or distribution, injunctions, fines,
refusals of government contracts, restitution, disgorgement or
civil or criminal penalties. Any agency or judicial enforcement
action could have a material adverse effect on
CEL-SCI.
The
requirements governing the conduct of clinical trials,
manufacturing and marketing of the product candidates, including
Multikine, outside the United States vary from country to country.
Foreign approvals may take longer to obtain than FDA approvals and
can require, among other things, additional testing and different
trial designs. Foreign regulatory approval processes include all of
the risks associated with the FDA approval process. Some of those
agencies also must approve prices for products approved for
marketing. Approval of a product by the FDA or the EMA does not
ensure approval of the same product by the health authorities of
other countries. In addition, changes in regulatory requirements
for product approval in any country during the clinical trial
process and regulatory agency review of each submitted new
application may cause delays or rejections.
CEL-SCI
has only limited experience in filing and pursuing applications
necessary to gain regulatory approvals. The lack of
experience may impede its ability to obtain timely approvals from
regulatory agencies, if at all. CEL-SCI will not be able to
commercialize Multikine and other product candidates until CEL-SCI
has obtained regulatory approval. In addition,
regulatory authorities may also limit the types of patients to
which CEL-SCI or its third-party partners may market Multikine (if
approved) or the other product candidates. Any failure to obtain or
any delay in obtaining required regulatory approvals may adversely
affect CEL-SCI’s or its third-party partners’ ability
to successfully market the product candidates after they are
approved.
Even if CEL-SCI obtains regulatory approval for its investigational
products, CEL-SCI will be subject to stringent, ongoing government
regulation.
If
CEL-SCI’s investigational products receive regulatory
approval, either in the United States or internationally, those
products will be subject to limitations on the approved indicated
uses for which the product may be marketed or to the conditions of
approval, and may contain requirements for potentially costly
post-marketing testing, including Phase 4 clinical trials, and
surveillance of the safety and efficacy of the investigational
products. CEL-SCI will continue to be subject to
extensive regulatory requirements. These regulations are
wide-ranging and govern, among other things:
●
product
design, development and manufacture;
●
product
application and use
●
adverse
drug experience monitoring reporting;
●
product
advertising and promotion;
●
product
manufacturing, including compliance with good manufacturing
practices
●
record
keeping requirements;
●
registration
and listing of the establishments and products with the FDA, EMA
and other state and national agencies;
●
product
storage and shipping;
●
drug
sampling and distribution requirements;
●
electronic
record and signature requirements; and
●
labeling
changes or modifications.
CEL-SCI
and any of its third-party manufacturers or suppliers must
continually adhere to federal regulations setting forth human drug
and biologic manufacturing requirements, known as current Good
Manufacturing Practices, or cGMPs, and their foreign equivalents,
which are enforced by the FDA, the EMA and other national
regulatory bodies through their facilities inspection programs. If
the facilities, or the facilities of the contract manufacturers or
suppliers, cannot pass a pre-approval inspection by regulators or
fail such inspections in the future, the FDA, EMA or other national
regulators will not approve the marketing applications for the
product candidates, or may withdraw any prior approval. In
complying with cGMP and foreign regulatory requirements, CEL-SCI
and any of its potential third-party manufacturers or suppliers
will be obligated to expend time, money and effort in production,
record-keeping and quality control to ensure that the product
candidates meet applicable specifications and other
requirements.
If
CEL-SCI does not comply with regulatory requirements at any stage,
whether before or after marketing approval is obtained, CEL-SCI may
be subject to, among other things, license suspension or
revocation, criminal prosecution, seizure, injunction, fines, be
forced to remove a product from the market or experience other
adverse consequences, including restrictions or delays in obtaining
regulatory marketing approval for such products or for other
product candidates for which CEL-SCI seeks
approval. This could materially harm CEL-SCI’s
financial results, reputation and stock price. Additionally,
CEL-SCI may not be able to obtain the labeling claims necessary or
desirable for product promotion. If CEL-SCI or other parties
identify adverse effects after any of the products are on the
market, or if manufacturing problems occur, regulatory approval may
be suspended or withdrawn. CEL-SCI may be required to reformulate
products, conduct additional clinical trials, make changes in
product labeling or indications of use, or submit additional
marketing applications to support any changes. If
CEL-SCI encounters any of the foregoing problems, its business and
results of operations will be harmed and the market price of its
common stock may decline.
The FDA and other governmental authorities’ policies may
change and additional government regulations may be enacted that
could prevent, limit or delay regulatory approval of
CEL-SCI’s product candidates. If CEL-SCI is slow or unable to
adapt to changes in existing requirements or the adoption of new
requirements or policies, or if CEL-SCI is not able to maintain
regulatory compliance, CEL-SCI may lose any marketing approval that
it may have obtained, which would adversely affect its business,
prospects and ability to achieve or sustain
profitability. CEL-SCI cannot predict the extent of
adverse government regulations which might arise from future
legislative or administrative action. Without government approval,
CEL-SCI will be unable to sell any of its product
candidates.
CEL-SCI’s product candidates may cause undesirable side
effects or have other properties that could delay or prevent their
regulatory approval, limit the commercial utility of an approved
prescribing label, or result in significant negative consequences
following marketing approval, if any.
Undesirable
side effects caused by its product candidates could cause CEL-SCI
or regulatory authorities to interrupt, delay or halt clinical
trials and could result in a more restrictive label or the delay or
denial of regulatory approval by the FDA or other comparable
foreign authorities. Results of the clinical trials could reveal a
high and unacceptable severity and/or prevalence of these or other
side effects. In such an event, the trials could be suspended or
terminated and the FDA or comparable foreign regulatory authorities
could order CEL-SCI to cease further development of, or deny
approval of, the product candidates for any or all targeted
indications. The drug-related side effects could affect patient
recruitment or the ability of enrolled patients to complete the
trial or result in potential product liability claims. Any of these
occurrences may harm CEL-SCI’s business, financial condition
and prospects significantly.
Additionally,
if one or more of the product candidates receives marketing
approval, and CEL-SCI or others later identify undesirable side
effects caused by such products, a number of potentially
significant negative consequences could result, including but not
limited to the following:
●
regulatory
authorities may withdraw approvals of such product or require
product recalls;
●
regulatory
authorities may require additional warnings on the label or impose
restrictions on product distribution or use;
●
regulatory authorities may require CEL-SCI
to conduct new post-marketing studies or clinical
trials;
●
CEL-SCI could
receive warning or untitled letters from the FDA or comparable
notice of violations from foreign regulatory
authorities;
●
CEL-SCI
may be required to create a medication guide outlining the risks of
such side effects for distribution to patients;
●
CEL-SCI
could be sued and held liable for harm caused to patients;
and
●
CEL-SCI’s
reputation may suffer.
Any
of these events could prevent CEL-SCI from achieving or maintaining
market acceptance of a particular product candidate, if approved,
and could significantly harm its business, results of operations
and prospects.
CEL-SCI relies on third parties to conduct its preclinical and
clinical trials. If these third parties do not successfully carry
out their contractual duties and meet regulatory requirements, or
meet expected deadlines, CEL-SCI may not be able to obtain
regulatory approval for or commercialize the product candidates and
its business could be substantially harmed.
CEL-SCI
does not have the ability to independently conduct clinical trials.
CEL-SCI has relied upon and plans to continue to rely upon
third-party CROs to prepare for, conduct, monitor and manage data
for its ongoing preclinical and clinical programs, including the
global Phase 3 trial for Multikine. CEL-SCI relies on these parties
for all aspects of the execution of its preclinical studies and
clinical trials, and although CEL-SCI diligently oversees and
carefully manages the CROs, CEL-SCI directly controls only certain
aspects of their activities and relies upon them to provide timely,
complete, and accurate reports on the conduct of the studies.
Although such third parties provide support and represent CEL-SCI
for regulatory purposes in the context of the clinical trials,
ultimately CEL-SCI is responsible for ensuring that each of the
studies is conducted in accordance with the applicable protocol,
legal, regulatory, and scientific standards, and the reliance on
the CROs does not relieve CEL-SCI of its regulatory
responsibilities. CEL-SCI and the CROs acting on CEL-SCI’s
behalf, as well as principal investigators and trial sites, are
required to comply with Good Clinical Practice, or GCP, and other
applicable requirements, which are implemented through regulations
and guidelines enforced by the FDA, the Competent Authorities of
the Member States of the European Economic Area, or EEA, and
comparable foreign regulatory authorities for all of the products
in clinical development. Regulatory authorities enforce these GCPs
through periodic inspections of trial sponsors, principal
investigators, and trial sites. If CEL-SCI or any of the CROs fail
to comply with applicable GCPs or other applicable regulations, the
clinical data generated in the clinical trials may be determined to
be unreliable and CEL-SCI may therefore need to enroll additional
subjects in the clinical trials, or the FDA, EMA or comparable
foreign regulatory authorities may require CEL-SCI to perform an
additional clinical trial or trials before approving the marketing
applications. Moreover, if CEL-SCI or any of the CROs, principal
investigators, or trial sites, fail to comply with applicable
regulatory and GCP requirements, CEL-SCI, the CROs, principal
investigators, or trial sites may be subject to enforcement
actions, such as fines, warning letters, untitled letters, clinical
holds, civil or criminal penalties, and/or injunctions. CEL-SCI
cannot assure you that upon inspection by a given regulatory
authority, such regulatory authority will determine that any of the
clinical trials comply with cGCP regulations. In addition, the
clinical trials must be conducted with product produced under cGMP
regulations. The failure to comply with these regulations may
require CEL-SCI to delay or repeat clinical trials, which would
delay the regulatory approval process.
If
any of the relationships with the third-party CROs terminate,
CEL-SCI may not be able to enter into arrangements with alternative
CROs or to do so on commercially reasonable terms. In addition, the
CROs are not CEL-SCI’s employees, and except for remedies
available to CEL-SCI under the agreements with such CROs, CEL-SCI
cannot control whether or not they devote sufficient time and
resources to the on-going clinical, nonclinical and preclinical
programs. If CROs do not successfully fulfill their regulatory
obligations, carry out their contractual duties or obligations or
meet expected deadlines, if they need to be replaced or if the
quality or accuracy of the clinical data they obtain is compromised
due to the failure to adhere to the clinical protocols, regulatory
requirements or for other reasons, the clinical trials may be
extended, delayed or terminated, and CEL-SCI may not be able to
obtain regulatory approval for, or successfully commercialize, the
product candidates. As a result, CEL-SCI’s results of
operations and the commercial prospects for the product candidates
would be harmed, the costs could increase and the ability to
generate revenues could be delayed.
Switching
or adding additional CROs involves additional cost and requires
management time and focus. In addition, there is a natural
transition period when a new CRO commences work. As a result,
delays may occur, which can materially impact CEL-SCI’s
ability to meet the desired clinical development timelines. Though
CEL-SCI diligently oversees and carefully manages its relationships
with the CROs, there can be no assurance that CEL-SCI will not
encounter similar challenges or delays in clinical development in
the future or that these delays or challenges will not have a
material adverse impact on CEL-SCI’s business, financial
condition and prospects.
CEL-SCI has obtained orphan drug designation from the FDA for
Multikine for neoadjuvant, or primary, therapy in patients with
squamous cell carcinoma of the head and neck, but CEL-SCI may be
unable to maintain the benefits associated with orphan drug
designation, including the potential for market
exclusivity.
Under
the Orphan Drug Act, the FDA may grant orphan drug designation to a
drug or biologic intended to treat a rare disease or condition,
which is defined as one occurring in a patient population of fewer
than 200,000 in the United States, or a patient population greater
than 200,000 in the United States where there is no reasonable
expectation that the cost of developing the drug or biologic will
be recovered from sales in the United States. In the United States,
orphan drug designation entitles a party to financial incentives
such as opportunities for grant funding towards clinical trial
costs, tax advantages and user-fee waivers. In addition, if a
product that has orphan drug designation subsequently receives the
first FDA approval for the disease for which it has such
designation, the product is entitled to orphan drug exclusivity,
which means that the FDA may not approve any other applications,
including a full BLA, to market the same biologic for the same
indication for seven years, except in limited circumstances, such
as a showing of clinical superiority to the product with orphan
drug exclusivity or where the manufacturer is unable to assure
sufficient product quantity.
Even
though CEL-SCI has received orphan drug designation for Multikine
for the treatment of squamous cell carcinoma of the head and neck,
CEL-SCI may not be the first to obtain marketing approval of a
product for the orphan-designated indication due to the
uncertainties associated with developing pharmaceutical products.
In addition, exclusive marketing rights in the United States may be
limited if CEL-SCI seeks approval for an indication broader than
the orphan-designated indication, or may be lost if the FDA later
determines that the request for designation was materially
defective or if CEL-SCI is unable to assure sufficient quantities
of the product to meet the needs of patients with the rare disease
or condition. Further, even if CEL-SCI obtains orphan drug
exclusivity for a product candidate, that exclusivity may not
effectively protect the product candidate from competition because
different drugs with different active moieties can be approved for
the same condition. Even after an orphan product is approved, the
FDA can subsequently approve another drug with the same active
moiety for the same condition if the FDA concludes that the later
drug is safer, more effective, or makes a major contribution to
patient care. Orphan drug designation neither shortens the
development time or regulatory review time of a drug nor gives the
drug any advantage in the regulatory review or approval
process.
Biologics carry unique risks and uncertainties, which could have a
negative impact on future results of CEL-SCI’s
operations.
The
successful discovery, development, manufacturing and sale of
biological products like CEL-SCI’s candidates is a long,
expensive and uncertain process. There are unique risks and
uncertainties with biologics. For example, access to and supply of
necessary biological materials, such as cell lines, may be limited
and governmental regulations restrict access to and regulate the
transport and use of such materials. In addition, the development,
manufacturing and sale of biologics is subject to regulations that
are often more complex and extensive than the regulations
applicable to other pharmaceutical products. Manufacturing
biologics, especially in large quantities, is often complex and may
require the use of innovative technologies. Such manufacturing also
requires facilities specifically designed and validated for this
purpose and sophisticated quality assurance and quality control
procedures. Biologics are also frequently costly to manufacture
because production inputs are derived from living animal or plant
material, and some biologics cannot be made synthetically. Failure
to successfully discover, develop, manufacture and sell its
biological product candidates would adversely impact
CEL-SCI’s business and future results of
operations.
CEL-SCI faces substantial competition, which may result in others
discovering, developing or commercializing competing products
before or more successfully than CEL-SCI.
The
development and commercialization of new drug and biological
products is highly competitive. CEL-SCI faces competition with
respect to its current product candidates and expects to face
competition with respect to any product candidates that CEL-SCI may
seek to develop or commercialize in the future, from major
pharmaceutical companies, specialty pharmaceutical companies and
biotechnology companies worldwide. Potential competitors also
include academic institutions, government agencies and other public
and private research organizations that conduct research, seek
patent protection and establish collaborative arrangements for
research, development, manufacturing and
commercialization.
Many of
the companies against which CEL-SCI is competing or against which
CEL-SCI may compete in the future have significantly greater
financial resources and expertise in research and development,
manufacturing, nonclinical studies, conducting clinical trials,
obtaining marketing approvals and marketing approved products than
CEL-SCI. Mergers and acquisitions in the pharmaceutical and
biotechnology industries may result in even more resources being
concentrated among a smaller number of CEL-SCI’s competitors.
Smaller and early-stage companies may also prove to be significant
competitors, particularly through collaborative arrangements with
large and established companies. These third parties compete with
CEL-SCI in recruiting and retaining qualified scientific and
management personnel, establishing clinical trial sites and patient
registration for clinical trials, as well as in acquiring
technologies complementary to, or necessary for, CEL-SCI’s
programs.
CEL-SCI may be unable to successfully scale-up manufacturing of its
lead product candidate Multikine in sufficient quality and
quantity, which would delay or prevent CEL-SCI from commercializing
this product, if approved for marketing by the FDA or other
regulatory agencies.
In
order to commercialize its product candidates, CEL-SCI will need to
manufacture them in large quantities. At the present time, CEL-SCI
is not manufacturing Multikine while CEL-SCI completes the
follow-up phase of its Phase 3 clinical trial. CEL-SCI is planning
to increase the capacity of its proprietary facility to produce
commercial quantities of Multikine, if approved, and is currently
exploring options for implementing scale-up activities in
anticipation of study completion and submitting applications for
marketing approval, if supported by the Phase 3 data. CEL-SCI may
be unable to successfully increase the manufacturing capacity for
its lead product candidate Multikine in a timely or cost-effective
manner, or at all. In addition, quality issues may arise during
scale-up activities.
Further, in order
to release product and demonstrate stability of product candidates
for future commercial use, CEL-SCI’s analytical methods must
be validated in accordance with regulatory guidelines. CEL-SCI may
not be able to successfully validate, or maintain validation of,
its analytical methods during scale-up or demonstrate adequate
purity, stability or comparability of the biological product
candidates in a timely or cost-effective manner, or at all. Even if
CEL-SCI believes its manufacturing processes meets all of the
regulatory manufacturing requirements, the FDA will review those
processes and the manufacturing facility as part of the review of
the future BLA for Multikine, if submitted after completion the
ongoing Phase 3 trial in advanced head and neck cancer. If CEL-SCI
is unable to successfully scale up the manufacture of Multikine in
sufficient quality and quantity, or if CEL-SCI encounters
validation issues, the development, testing, and clinical trials of
future product candidates, may be delayed or infeasible, and
regulatory approval or commercial launch of any resulting product,
including Multikine, may be delayed or may not be successfully
achieved.
The current and future relationships with healthcare professionals,
principal investigators, consultants, potential customers and
third-party payors in the United States and elsewhere may be
subject, directly or indirectly, to applicable healthcare laws and
regulations.
Although
CEL-SCI does not currently have any products on the market, once
CEL-SCI begins commercializing its product candidates, CEL-SCI will
be subject to additional healthcare statutory and regulatory
requirements and oversight by federal and state governments as well
as foreign governments in the jurisdictions in which CEL-SCI
conducts its business. Healthcare providers, physicians and
third-party payors in the United States and elsewhere will play a
primary role in the recommendation and prescription of any drug
candidates for which CEL-SCI obtains marketing approval. The
current and future arrangements with healthcare professionals,
principal investigators, consultants, potential customers and
third-party payors may expose CEL-SCI to broadly applicable
healthcare laws, including, without limitation:
●
the
federal Anti-Kickback Statute, which prohibits, among other things,
persons from knowingly and willfully soliciting, offering,
receiving or providing remuneration, directly or indirectly, in
cash or in kind, to induce or reward, or in return for, either the
referral of an individual for, or the purchase, lease, order or
recommendation of, any good, facility, item or service, for which
payment may be made, in whole or in part, under federal and state
healthcare programs such as Medicare and Medicaid. A person or
entity does not need to have actual knowledge of the statute or
specific intent to violate it to have committed a violation. In
addition, the Affordable Care Act provides that the government may
assert that a claim including items or services resulting from a
violation of the federal Anti-Kickback Statute constitutes a false
or fraudulent claim for purposes of the False Claims
Act;
●
federal
civil and criminal false claims laws, including the federal False
Claims Act, which impose criminal and civil penalties, including
civil whistleblower actions, against individuals or entities for,
among other things, knowingly presenting, or causing to be
presented, to the federal government, including the Medicare and
Medicaid programs, claims for payment that are false or fraudulent
or making a false statement to avoid, decrease or conceal an
obligation to pay money to the federal government;
●
the
federal Health Insurance Portability and Accountability Act of
1996, or HIPAA, which created new federal criminal statutes that
prohibit knowingly and willfully executing, or attempting to
execute, a scheme to defraud any healthcare benefit program or
obtain, by means of false or fraudulent pretenses, representations
or promises, any of the money or property owned by, or under the
custody or control of, any healthcare benefit program, regardless
of the payor (e.g., public or private), knowingly and willfully
embezzling or stealing from a health care benefit program,
willfully obstructing a criminal investigation of a healthcare
offense and knowingly and willfully falsifying, concealing or
covering up by any trick or device a material fact or making any
materially false statements in connection with the delivery of, or
payment for, healthcare benefits, items or services relating to
healthcare matters. A person or entity does not need to have actual
knowledge of the statute or specific intent to violate it to have
committed a violation;
●
HIPAA,
which also imposes obligations on covered entities, including
healthcare providers, health plans, and healthcare clearinghouses,
as well as their respective business associates that create,
receive, maintain or transmit individually identifiable health
information for or on behalf of a covered entity, with respect to
safeguarding the privacy, security and transmission of individually
identifiable health information;
●
the
U.S. federal physicians payment transparency requirements,
sometimes called the “Sunshine Act” and its
implementing regulations, which requires certain manufacturers of
drugs, devices, biologicals and medical supplies that are
reimbursable under Medicare, Medicaid, or the Children’s
Health Insurance Program to report to the Centers for Medicare
& Medicaid Services, or CMS, information related to physician
payments and “other transfers of value” to physicians
and teaching hospitals (and, beginning in 2021, for transfers of
value to other healthcare providers), as well as the ownership and
investment interests held by physicians and their immediate family
members;
●
analogous
state and foreign laws, such as state anti-kickback and false
claims laws, which may apply to sales or marketing arrangements and
claims involving healthcare items or services reimbursed by
non-governmental third-party payors, including private insurers;
state laws that require pharmaceutical companies to comply with the
pharmaceutical industry’s voluntary compliance guidelines and
the relevant compliance guidance promulgated by the federal
government or otherwise restrict payments that may be made to
healthcare providers; state and foreign laws that require drug
manufacturers to report information related to payments and other
transfers of value to physicians and other healthcare providers or
marketing expenditures; and state and foreign laws governing the
privacy and security of health information in certain
circumstances, many of which differ from each other in significant
ways and often are not preempted by HIPAA, thus complicating
compliance efforts;
●
the U.S. federal
laws that require pharmaceutical manufacturers to report certain
calculated product prices to the government or provide certain
discounts or rebates to government authorities or private entities,
often as a condition of reimbursement under federal healthcare
programs; and
●
state and foreign
laws that govern the privacy and security of health information in
certain circumstances, including state security breach notification
laws, state health information privacy laws and federal and state
consumer protection laws, many of which differ from each other in
significant ways and often are not preempted by HIPAA, thus
complicating compliance efforts.
Efforts
to ensure that the future business arrangements with third parties
will comply with applicable healthcare laws and regulations may
involve substantial costs. It is possible that governmental
authorities will conclude that the business practices may not
comply with current or future statutes, regulations or case law
involving applicable fraud and abuse or other healthcare laws. If
CEL-SCI’s operations are found to be in violation of any of
these laws or any other governmental regulations, CEL-SCI may be
subject to significant civil, criminal and administrative
penalties, including, without limitation, damages, fines,
imprisonment, exclusion from participation in government healthcare
programs, such as Medicare and Medicaid, and the curtailment or
restructuring of the operations, all of which could significantly
harm CEL-SCI’s business. If any of the physicians or other
healthcare providers or entities with whom CEL-SCI expects to do
business, including current and future collaborators, are found not
to be in compliance with applicable laws, they may be subject to
criminal, civil or administrative sanctions, including exclusions
from participation in government healthcare programs, which could
also adversely affect CEL-SCI’s
business.
Failure to obtain or maintain adequate coverage and reimbursement
for the product candidates, if approved, couldlimit the ability to
market those products and decrease CEL-SCI’s ability to
generate revenue.
Sales
of CEL-SCI’s product candidates will depend substantially,
both domestically and abroad, on the extent to which the costs of
the approved products will be paid by health maintenance, managed
care, pharmacy benefit, and similar healthcare management
organizations, or reimbursed by government authorities, private
health insurers and other third-party payors. CEL-SCI anticipates
that government authorities and other third-party payors will
continue efforts to contain healthcare costs by limiting the
coverage and reimbursement levels for new drugs and biologics. If
coverage and reimbursement are not available, or are available only
to limited levels, CEL-SCI may not be able to successfully
commercialize its product candidates. Even if coverage is provided,
the approved reimbursement amount may not be high enough to allow
CEL-SCI to establish or maintain pricing sufficient to realize a
return on its investment. It is difficult to predict at this time
what third-party payors will decide with respect to the coverage
and reimbursement for CEL-SCI’s product
candidates.
Moreover,
in some countries, particularly the countries of the European
Union, the pricing of prescription pharmaceuticals is subject to
governmental control. In these countries, pricing negotiations with
governmental authorities can take considerable time after the
receipt of marketing approval for a product. To obtain
reimbursement or pricing approval in some countries, CEL-SCI may be
required to conduct a clinical trial that compares the
cost-effectiveness of its product candidate to other available
therapies. If reimbursement of its products is unavailable or
limited in scope or amount, or if pricing is set at unsatisfactory
levels, CEL-SCI’s business could be harmed, possibly
materially.
Even if any of CEL-SCI’s product candidates receives
marketing approval, it may fail to achieve the degree of market
acceptance by physicians, patients, third-party payors and others
in the medical community necessary for commercial
success.
If
any of CEL-SCI’s product candidates receives marketing
approval, it may nonetheless fail to gain sufficient market
acceptance by physicians, patients, third-party payors and others
in the medical community. If CEL-SCI’s product candidates do
not achieve an adequate level of acceptance, CEL-SCI may not
generate significant product revenues and CEL-SCI may not become
profitable. The degree of market acceptance of its product
candidates, including Multikine if approved for commercial sale,
will depend on a number of factors, including:
●
the
timing of CEL-SCI’s receipt of any marketing
approvals;
●
the
terms of any approvals and the countries in which approvals are
obtained;
●
the
efficacy and safety and potential advantages and disadvantages
compared to alternative treatments, including future alternative
treatments;
●
the
prevalence and severity of any side effects associated with
CEL-SCI’s product candidates;
●
the
indications for which its products are approved and the scope of
risk information required to be included in the product
labeling;
●
adverse
publicity about it’s products or favorable publicity about
competing products;
●
the
approval of other products for the same indications as
CEL-SCI’s products;
●
CEL-SCI’s
ability to offer CEL-SCI’s products for sale at competitive
prices;
●
the
convenience and ease of administration compared to alternative
treatments;
●
the
willingness of the target patient population to try new therapies
and of physicians to prescribe these therapies;
●
the
success of CEL-SCI’s physician education
programs;
●
the
strength of CEL-SCI’s marketing and distribution support;
and
●
the
availability of third-party coverage and adequate
reimbursement.
If
any product candidate CEL-SCI commercializes fails to achieve
market acceptance, it could have a material and adverse effect on
CEL-SCI’s business, financial condition, results of operation
and prospects.
CEL-SCI currently has no marketing and sales force. If CEL-SCI is
unable to establish effective sales or marketing capabilities or
enter into agreements with third parties to sell or market its
product candidates, CEL-SCI may not be able to effectively sell or
market its product candidates, if approved, or generate product
revenues.
CEL-SCI
currently has a no sales and marketing infrastructure due to the
fact that all of its product candidates are still in clinical
development. To achieve commercial success for any approved product
candidate for which CEL-SCI retains sales and marketing
responsibilities, CEL-SCI must build its sales, marketing,
managerial, and other non-technical capabilities or make
arrangements with third parties to perform these services. For
example, CEL-SCI has entered into agreements with certain foreign
distributors to commercialize Multikine, if approved, within their
respective territories. However, CEL-SCI may determine that there
is a need to building its own sales force in the United States for
the future marketing of Multikine, if approved, rather than seeking
a U.S. co-marketing partner or relying on a contracted sales force.
There are risks involved with either establishing its own sales and
marketing capabilities or entering into arrangements with third
parties to perform these services. For example, recruiting and
training a sales force is expensive and time consuming and could
delay any product launch. If the commercial launch of a product
candidate for which CEL-SCI recruits a sales force and establishes
marketing capabilities is delayed or does not occur for any reason,
CEL-SCI would have prematurely or unnecessarily incurred these
commercialization expenses. This may be costly, and its investment
would be lost if CEL-SCI cannot retain or reposition its sales and
marketing personnel.
Factors
that may inhibit CEL-SCI’s efforts to commercialize its
product candidates on its own include:
●
CEL-SCI’s
inability to recruit, hire, retain and incentivize adequate numbers
of effective sales and marketing personnel;
●
the
inability of sales personnel to obtain access to physicians or
persuade adequate numbers of physicians to use and administer
CEL-SCI’s future products;
●
the
lack of complementary products to be offered by sales personnel,
which may put CEL-SCI at a competitive disadvantage relative to
companies with more extensive product lines; and
●
unforeseen
costs and expenses associated with establishing an independent
sales and marketing organization.
If
CEL-SCI does not establish sales and marketing capabilities
successfully, either on its own or in collaboration with third
parties, CEL-SCI will not be successful in commercializing
Multikine, if approved, or any of its other product candidates that
receive marketing approval or any such commercialization may
experience delays or limitations.
CEL-SCI’s business activities may be subject to the Foreign
Corrupt Practices Act and similar anti-bribery and anti-corruption
laws of other countries in which CEL-SCI operates or will operate
in the future.
CEL-SCI
has conducted and has ongoing studies in international locations,
and may in the future initiate additional studies in countries
other than the United States. Moreover, CEL-SCI has entered into
agreements with foreign distributors to commercialize Multikine, if
approved, in various territories outside of the United States. As a
result, CEL-SCI’s business activities may be subject to the
Foreign Corrupt Practices Act, or FCPA, and similar anti-bribery or
anti-corruption laws, regulations or rules of other countries in
which CEL-SCI operates. The FCPA generally prohibits offering,
promising, giving or authorizing others to give anything of value,
either directly or indirectly, to a non-U.S. government official in
order to influence official action or otherwise obtain or retain
business. The FCPA also requires public companies to make and keep
books and records that accurately and fairly reflect the
transactions of the corporation and to devise and maintain an
adequate system of internal accounting controls.
CEL-SCI’s
business is heavily regulated and therefore involves significant
interaction with public officials, including officials of non-U.S.
governments. Additionally, in many other countries, the healthcare
providers who prescribe biopharmaceuticals are employed by their
government, and the purchasers of biopharmaceuticals are government
entities; therefore, CEL-SCI’s dealings with these
prescribers and purchasers are subject to regulation under the
FCPA. Recently the SEC and Department of Justice have increased
their FCPA enforcement activities with respect to biotechnology and
pharmaceutical companies. There is no certainty that all of
CEL-SCI’s employees, agents or contractors conducting
business abroad will comply with all applicable laws and
regulations, particularly given the high level of complexity of
these laws. Violations of these laws and regulations could result
in fines, criminal sanctions against CEL-SCI, its officers or
employees, the closing of CEL-SCI’s facilities, requirements
to obtain export licenses, cessation of business activities in
sanctioned countries, implementation of compliance programs and
prohibitions on the conduct of CEL-SCI’s business. Any such
violations could include prohibitions on CEL-SCI’s ability to
offer its product candidates, if approved, in one or more countries
and could materially damage its reputation, its brand, its future
international marketing efforts, its ability to attract and retain
employees and its business, prospects, operating results and
financial condition.
Healthcare legislative reform measures may have a material adverse
effect on CEL-SCI’s business and results of
operations.
Existing
regulatory policies may change and additional government
regulations may be enacted that could prevent, limit or delay
regulatory approval of CEL-SCI’s product candidates. CEL-SCI
cannot predict the likelihood, nature or extent of government
regulation that may arise from future legislation or administrative
action, either in the United States or abroad. If CEL-SCI is slow
or unable to adapt to changes in existing requirements or the
adoption of new requirements or policies, or if CEL-SCI is not able
to maintain regulatory compliance, CEL-SCI may lose any marketing
approval that it may have obtained and it may not achieve or
sustain profitability.
In
the United States, there have been and continue to be a number of
legislative initiatives to contain healthcare costs that may result
in more limited coverage or downward pressure on the price CEL-SCI
may otherwise receive for its product candidates. For example, in
March 2010, Congress passed the Patient Protection and Affordable
Care Act, as amended by the Health Care and Education
Reconciliation Act, or collectively, the Affordable Care Act, which
expanded healthcare coverage through Medicaid expansion and the
implementation of the individual mandate for health insurance
coverage and which included changes to the coverage and
reimbursement of drug products under federal healthcare programs.
The ACA contains a number of provisions that affect coverage and
reimbursement of drug and biological products and/or that could
potentially reduce the demand for pharmaceutical products such as
increasing drug rebates under state Medicaid programs for brand
name prescription drugs and extending those rebates to Medicaid
managed care and assessing a fee on manufacturers and importers of
brand name prescription drugs reimbursed under certain government
programs, including Medicare and Medicaid. Under the Trump
administration, there have been ongoing efforts to modify or repeal
all or certain provisions of the ACA. For example, tax reform
legislation was enacted at the end of 2017 that eliminates the tax
penalty established under the ACA for individuals who do not
maintain mandated health insurance coverage beginning in 2019. In a
May 2018 report, the Congressional Budget Office estimated that,
compared to 2018, the number of uninsured will increase by 3
million in 2019 and 6 million in 2028, in part due to the
elimination of the individual mandate. The ACA has also been
subject to judicial challenge. In December 2018, a federal district
court, in a challenge brought by a number of state attorneys
general, found the ACA unconstitutional in its entirety because,
once Congress repealed the individual mandate provision, there was
no longer a basis to rely on Congressional taxing authority to
support enactment of the law. Pending appeals, which could take
some time, the ACA is still operational in all
respects.
CEL-SCI’s
industry continues to face potential changes in the legal and
regulatory landscape on the federal, state and international
levels. Additional legislative actions to control U.S. healthcare
or other costs have passed. The Budget Control Act, as amended,
resulted in the imposition of 2% reductions in Medicare (but not
Medicaid) payments to providers in 2013 and will remain in effect
through 2027 unless additional Congressional action is taken. There
has also been increasing and considerable public and government
interest in the United States with respect to specialty drug
pricing practices, including proposed federal and state legislation
designed to bring more transparency to drug pricing, reduce the
cost of prescription drugs under Medicare, review the relationship
between pricing and manufacturer patient programs, put in place
limits and caps on pharmaceutical prices, request rebates for
certain pharmaceutical products, and reform government program
reimbursement methodologies for drugs. In addition, regional
healthcare authorities and individual hospitals are increasingly
using bidding procedures to determine what biopharmaceutical
products and which suppliers will be included in their prescription
drug and other healthcare programs. In markets outside of the
United States, reimbursement and healthcare payment systems vary
significantly by country, and many countries have instituted price
ceilings on specific products and therapies. For example, the
European Union provides options for its member states to restrict
the range of medicinal products for which their national health
insurance systems provide reimbursement and control the prices of
medicinal products for human use.
CEL-SCI
expects that current or future healthcare reform measures may
result in more rigorous coverage criteria and in additional
downward pressure on the price that it receives for any approved
product, including Multikine if it is approved for
commercialization. Any reduction in reimbursement from Medicare or
other government programs may result in a similar reduction in
payments from private payors. The implementation of cost
containment measures or other healthcare reforms may prevent
CEL-SCI from being able to generate revenue, attain profitability
or commercialize its product candidates.
Legislative
and regulatory proposals also have been made to expand
post-approval requirements and restrict sales and promotional
activities for biotechnology products. CEL-SCI cannot be sure
whether additional legislative changes will be enacted, or whether
FDA regulations, guidance or interpretations for biological
products will be changed, or what the impact of such changes on the
marketing approvals of its product candidates, if any, may be. In
addition, increased scrutiny by the U.S. Congress of the
FDA’s approval and decision-making processes may
significantly delay or prevent marketing approval, as well as
subject CEL-SCI to more stringent product labeling and
post-marketing testing and other requirements.
Foreign governments often impose strict price controls, which may
adversely affect CEL-SCI’s future profitability.
CEL-SCI
intends to seek approval to market its lead investigational
product, Multikine, in both the United States and foreign
jurisdictions. If CEL-SCI obtains approval in one or more foreign
jurisdictions, CEL-SCI will be subject to rules and regulations in
those jurisdictions relating to Multikine. In some foreign
countries, particularly in the European Union, prescription drug
pricing is subject to governmental control. In these countries,
pricing negotiations with governmental authorities can take
considerable time after the receipt of marketing approval for a
drug candidate. Coverage and reimbursement decisions in one foreign
jurisdiction may impact decisions in other countries. To obtain
reimbursement or pricing approval in some countries, CEL-SCI may be
required to conduct clinical trials that demonstrate the product
candidate is more effective than current treatments and that
compare the cost-effectiveness of Multikine to other available
therapies. If reimbursement of Multikine is unavailable or limited
in scope or amount, or if pricing is set at unsatisfactory levels,
CEL-SCI may be unable to achieve or sustain
profitability.
If CEL-SCI fails to comply with environmental, health and safety
laws and regulations, CEL-SCI could become subject to fines or
penalties or incur costs that could harm its business.
CEL-SCI
is subject to numerous environmental, health and safety laws and
regulations, including those governing laboratory procedures and
the handling, use, storage, treatment and disposal of hazardous
materials and wastes generated in its biologic manufacturing
facility. CEL-SCI cannot eliminate the risk of contamination or
injury from these materials. In the event of contamination or
injury resulting from its use of hazardous materials, including
radioactive materials used in its research laboratory, CEL-SCI
could be held liable for any resulting damages, and the amount of
the liability could exceed its resources. CEL-SCI also could incur
significant costs associated with civil or criminal fines and
penalties for failure to comply with such laws and
regulations.
Risks Related to Intellectual Property
CEL-SCI may not be able to achieve or maintain a competitive
position, and other technological developments may result in its
proprietary technologies becoming uneconomical or
obsolete.
CEL-SCI
is involved in a biomedical field that is undergoing rapid and
significant technological change. The pace of change continues to
accelerate. The successful development of product
candidates from the compounds, compositions and processes, through
research financed by CEL-SCI, or as a result of possible
third-party licensing arrangements with pharmaceutical or other
companies, is not assured. CEL-SCI may fail to apply for
patents on important technologies or product candidates in a timely
fashion, or at all.
Many
companies are working on drugs designed to cure or treat cancer or
cure and treat viruses, such as HPV or H1N1. Many of
these companies have financial, research and development, and
marketing resources, which are much greater than CEL-SCI’s,
and are capable of providing significant long-term competition
either by establishing in-house research groups or by forming
collaborative ventures with other entities. In addition, smaller
companies and non-profit institutions are active in research
relating to cancer and infectious diseases. The future
market share of Multikine or the other product candidates, if
approved, will be reduced or eliminated if the competitors develop
and obtain approval for products that are safer or more effective
than CEL-SCI’S product candidates. Moreover, the
patent positions of pharmaceutical companies are highly uncertain
and involve complex legal and factual questions for which important
legal principles are often evolving and remain unresolved. As a
result, the validity and enforceability of patents cannot be
predicted with certainty. In addition, CEL-SCI does not know
whether:
●
CEL-SCI
was the first to make the inventions covered by each of its issued
patents and pending patent applications;
●
CEL-SCI
was the first to file patent applications for these
inventions;
●
others
will independently develop similar or alternative technologies or
duplicate any of CEL-SCI’s technologies;
●
any
of the pending patent applications will result in issued
patents;
●
any
of the patents will be valid or enforceable;
●
any
patents issued to CEL-SCI or its collaboration partners will
provide CEL-SCI with any competitive advantages, or will be
challenged by third parties;
●
CEL-SCI
will be able to develop additional proprietary technologies that
are patentable;
●
the
U.S. government will exercise any of its statutory rights to
CEL-SCI’s intellectual property that was developed with
government funding; or
●
its
business may infringe the patents or other proprietary rights of
others.
CEL-SCI’s patents might not protect its technology from
competitors, in which case CEL-SCI may not have any advantage over
competitors in selling any products that CEL-SCI may
develop.
CEL-SCI’s
commercial success will depend in part on its ability to obtain
additional patents and protect its existing patent position, as
well as its ability to maintain adequate intellectual property
protection for the technologies, product candidates, and any future
products in the United States and other countries. If CEL-SCI does
not adequately protect its technology, product candidates and
future products, competitors may be able to use or practice them
and erode or negate any competitive advantage CEL-SCI may have,
which could harm CEL-SCI’s business and its ability to
achieve profitability. The laws of some foreign countries do not
protect the proprietary rights to the same extent or in the same
manner as U.S. laws, and CEL-SCI may encounter significant problems
in protecting and defending its proprietary rights in these
countries. CEL-SCI will be able to protect its proprietary rights
from unauthorized use by third parties only to the extent that its
proprietary technologies, product candidates and any future
products are covered by valid and enforceable patents or are
effectively maintained as trade secrets.
Certain
aspects of CEL-SCI’s technologies are covered by U.S. and
foreign patents. In addition, CEL-SCI has a number of new patent
applications pending. There is no assurance that the applications
still pending or which may be filed in the future will result in
the issuance of any patents. Furthermore, there is no assurance as
to the breadth and degree of protection any issued patents might
afford CEL-SCI. Disputes may arise between CEL-SCI and others as to
the scope and validity of these or other patents. Any defense of
the patents could prove costly and time consuming and there can be
no assurance that CEL-SCI will be in a position, or will deem it
advisable, to carry on such a defense. A suit for patent
infringement could result in increasing costs, delaying or halting
development, or even forcing CEL-SCI to abandon a product
candidate. Other private and public concerns, including
universities, may have filed applications for, may have been
issued, or may obtain additional patents and other proprietary
rights to technology potentially useful or necessary to CEL-SCI.
CEL-SCI is not currently aware of any such patents, but the scope
and validity of such patents, if any, and the cost and availability
of such rights are impossible to predict.
Much of CEL-SCI’s intellectual property is protected as trade
secrets or confidential know-how, not as a patent.
CEL-SCI
considers proprietary trade secrets and/or confidential and
unpatented know-how to be important to its
business. Much of the intellectual property pertains to
CEL-SCI’S manufacturing system, certain aspects of which may
not be suitable for patent filings and must be protected as trade
secrets and/or confidential know-how. This type of
information must be protected diligently by CEL-SCI to protect its
disclosure to competitors, since legal protections after disclosure
may be minimal or non-existent. Accordingly, much of the
value of this intellectual property is dependent upon the ability
of CEL-SCI to keep its trade secrets and know-how
confidential.
To
protect this type of information against disclosure or
appropriation by competitors, CEL-SCI’s policy is to require
its employees, consultants, contractors and advisors to enter into
confidentiality agreements with CEL-SCI. However, current or former
employees, consultants, contractors and advisers may
unintentionally or willfully disclose the confidential information
to competitors, and confidentiality agreements may not provide an
adequate remedy in the event of unauthorized disclosure of
confidential information. Enforcing a claim that a third party
obtained illegally, and is using, trade secrets and/or confidential
know-how is expensive, time consuming and unpredictable. The
enforceability of confidentiality agreements may vary from
jurisdiction to jurisdiction.
In
addition, in some cases a regulator considering the application for
product candidate approval may require the disclosure of some or
all of the proprietary information. In such a case,
CEL-SCI must decide whether to disclose the information or forego
approval in a particular country. If CEL-SCI is unable
to market its product candidates in key countries, CEL-SCI’s
opportunities and value may suffer.
Failure
to obtain or maintain trade secrets and/or confidential know-how
trade protection could adversely affect CEL-SCI’S competitive
position. Moreover, competitors may independently develop
substantially equivalent proprietary information and may even apply
for patent protection in respect of the same. If successful in
obtaining such patent protection, competitors could limit the use
of such trade secrets and/or confidential know-how.
CEL-SCI may be subject to claims challenging the inventorship or
ownership of its patents and other intellectual
property.
CEL-SCI
may also be subject to claims that former employees, collaborators
or other third parties have an ownership interest in its patents or
other intellectual property. CEL-SCI may be subject to ownership
disputes in the future arising, for example, from conflicting
obligations of consultants or others who are involved in developing
the product candidates. Litigation may be necessary to defend
against these and other claims challenging inventorship or
ownership. If CEL-SCI fails in defending any such claims, in
addition to paying monetary damages, CEL-SCI may lose valuable
intellectual property rights, such as exclusive ownership of, or
right to use, valuable intellectual property. Such an outcome could
have a material adverse effect on its business. Even if CEL-SCI is
successful in defending against such claims, litigation could
result in substantial costs and be a distraction to CEL-SCI’s
management and employees.
Risks Related to CEL-SCI’s common stock
You may experience future dilution as a result of future equity
offerings or other equity issuances.
CEL-SCI
expects that significant additional capital will be needed in the
future to continue its planned operations. To raise additional
capital, CEL-SCI may in the future offer additional shares of its
common stock or other securities convertible into or exchangeable
for its common stock. To the extent CEL-SCI
raises additional capital by issuing equity securities,
CEL-SCI’s stockholders may experience substantial dilution.
These sales may result in material dilution to CEL-SCI’s
existing stockholders and new investors could gain rights superior
to existing stockholders.
CEL-SCI’s outstanding options and warrants may adversely
affect the trading price of its common stock.
As
of September 30, 2019, there were outstanding warrants which allow
the holders to purchase 5,772,303 shares of common stock, with a
weighted average exercise price of $7.70 per share, and outstanding
options which allow the holders to purchase up to 6,218,216 shares
of common stock, with a weighted average exercise price of $5.54
per share. The outstanding options and warrants could adversely
affect the ability of CEL-SCI to obtain future financing or engage
in certain mergers or other transactions, since the holders of
options and warrants can be expected to exercise them at a time
when CEL-SCI may be able to obtain additional capital through a new
offering of securities on terms more favorable to CEL-SCI than the
terms of the outstanding options and warrants. For the life
of the options and warrants, the holders have the opportunity to
profit from a rise in the market price of its common stock without
assuming the risk of ownership. The issuance of shares upon
the exercise or conversion of outstanding options and warrants will
also dilute the ownership interests of CEL-SCI’s existing
stockholders.
Since CEL-SCI does not intend to pay dividends on its common stock,
any potential return to investors will result only from any
increases in the price of its common stock.
At the present time, CEL-SCI intends to use available funds to
finance its operations. Accordingly, while payment of dividends
rests within the discretion of its board of directors, no common
stock dividends have been declared or paid by CEL-SCI and CEL-SCI
has no intention of paying any common stock dividends in the
foreseeable future. Additionally, any future debt financing
arrangement may contain terms prohibiting or limiting the amount of
dividends that may be declared or paid on CEL-SCI’s common
stock. Any return to CEL-SCI’s shareholders will
therefore be limited to appreciation in the price of its common
stock, which may never occur. If CEL-SCI’s stock
price does not increase, CEL-SCI’S shareholders are unlikely
to receive any return on their investments in CEL-SCI’s
common stock.
The price of CEL-SCI’s common stock has been volatile and is
likely to continue to be volatile, which could result in
substantial losses for CEL-SCI’s shareholders.
CEL-SCI’s
stock price has been, and is likely to continue to be, volatile. As
a result of this volatility, CEL-SCI’s shareholders may not
be able to sell their shares at or above its current market price.
The market price for CEL-SCI’s common stock may be influenced
by many factors, including:
●
actual
or anticipated fluctuations in CEL-SCI’s financial condition
and operating results;
●
actual
or anticipated changes in CEL-SCI’s growth rate relative to
competitors;
●
competition
from existing products or new products or product candidates that
may emerge;
●
development
of new technologies that may make CEL-SCI’s technology less
attractive;
●
changes
in physician, hospital or healthcare provider practices that may
make CEL-SCI’s product candidates less useful;
●
announcements
by CEL-SCI, its partners or competitors of significant
acquisitions, strategic partnerships, joint ventures,
collaborations or capital commitments;
●
developments
or disputes concerning patent applications, issued patents or other
proprietary rights;
●
the
recruitment or departure of key personnel;
●
failure
to meet or exceed financial estimates and projections of the
investment community or that CEL-SCI provides to the
public;
●
actual
or anticipated changes in estimates as to financial results,
development timelines or recommendations by securities
analysts;
●
variations
in its financial results or those of companies that are perceived
to be similar to CEL-SCI;
●
changes
to coverage and reimbursement levels by commercial third-party
payors and government payors, including Medicare, and any
announcements relating to reimbursement levels;
●
general
economic, industry and market conditions; and
●
the
other factors described in this “Risk Factors”
section.
ITEM
1B.
UNRESOLVED
SEC COMMENTS
None